Page last updated: 2024-08-25

zoledronic acid and Prostatic Neoplasms

zoledronic acid has been researched along with Prostatic Neoplasms in 408 studies

Research

Studies (408)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	191 (46.81)	29.6817
2010's	198 (48.53)	24.3611
2020's	19 (4.66)	2.80

Authors

Authors	Studies
Lewis, K; Marongiu, A; Massey, L; Rider, A; Seesaghur, A; von Moos, R	1
Errani, C; Marchetti, A; Massari, F; Mollica, V; Nigro, MC; Nuvola, G; Rizzo, A; Rosellini, M; Tassinari, E	1
Brockstedt, HK; Harsløf, T; Langdahl, B; Sølling, AS	1
Ahlers, AK; Baranowsky, A; Böckelmann, LC; Freytag, V; Gosau, T; Haider, MT; Lange, T; Maar, H; Pantel, K; Schmitz, R; Schumacher, U	1
Chen, M; Huang, M; Jiao, Y; Pan, J; Sun, Z; Wang, S; Ye, G; Ye, W; Zhang, D; Zhao, J	1
Iijima, H; Imamura, M; Ito, K; Kumagai, M; Muro, Y; Shiraishi, Y; Yabusaki, R; Yoshimura, K	1
Aragão Magalhães, I; Aragão Matos Carlos, AC; Da Silva Júnior, JE; De Barros Silva, PG; Fontes Borges, MM; Gonzaga Silva, LF; Moreira Caetano Coelho, L; Nóbrega Malta, CE	1
Diel, I; Holtmann, L; Kerkmann, M; Link, H; Ohlmann, CH	1
George, DJ	1
Beidas, RS; Bekelman, JE; Ladage, VP; Mace, DS; Shulman, LN; Takvorian, SU; Wileyto, EP	1
Ohta, K; Yoshimura, H	1
Griebling, TL	1
Ishibashi, M; Kakimoto, KI; Kanaki, T; Nagahara, A; Nakai, Y; Nakayama, M; Nishimura, K; Tanaka, R; Yamamoto, A; Yamamoto, Y	1
Gokalp, C	1
Cheng, Y; Ji, QF; Liu, DZ; Liu, M; Mei, QB; Yang, Q; Zhou, SY	1
Adams, A; Heidenreich, A; Jakob, T; Kuhr, K; Macherey, S; Monsef, I; Skoetz, N; Tesfamariam, YM	1
Kimura, T; Minowa, T; Mizushima, A; Takano, H; Uehara, Y; Watanabe, D; Watanabe, K; Yamashita, A; Yoshikawa, S	1
Hakim, SG; Pries, R; Simon, R; Steller, D; Von Bialy, R	1
Cruz, C; Miyashita, H; Patel, V	1
Aldinucci, D; Amler, E; Boccellino, M; Borghese, C; Caraglia, M; Casagrande, N; Colombatti, A; De Rosa, G; Normanno, N; Pivetta, E	1
Brezina, T; Cristino, J; Finek, J; Giannopoulou, C; Jandova, P; Kolek, M; Lothgren, M; Pásztor, B; Qian, Y	1
Saad, F; Traboulsi, SL	1
Hamid, AA; Sweeney, CJ	1
Beth-Tasdogan, NH; Hussein, H; Mayer, B; Zolk, O	1
Altrock, E; Bieback, K; Ghura, H; Groth, C; Hennenlotter, J; Jakob, F; Kuhlmann, JD; Link, T; Nakchbandi, IA; Rojewski, M; Rossnagl, S; Schott, S; Stenzl, A; Todenhöfer, T; Wimberger, P	1
Bulsara, M; Denham, JW; Ebert, MA; Haworth, A; Joseph, DJ; Kearvell, R; Kennedy, A; Marcello, M; Steigler, A	1
Abernethy, AP; Alan Brookhart, M; Butler, AM; Cetin, K; Diane Reams, B; Hernandez, RK; Hirsch, BR; I Kim, J; Liede, A; Overman, RA	1
Davidson, SE; Garcez, K; Henson, CC; Higham, CE; van den Blink, QU	1
Arai, Y; Kawakami, S; Kitayama, S; Otsuka, Y; Shirotake, S; Yano, A	1
Burdett, S; Carpenter, JR; Clarke, NW; Fisher, DJ; Fizazi, K; Gravis, G; James, ND; Mason, MD; Parmar, MKB; Rydzewska, LH; Spears, MR; Sweeney, CJ; Sydes, MR; Tierney, JF; Vale, CL; White, IR	1
Berk, LB; Clarkson, JE; Clausen, CL; Cleary, SF; Demas, W; Derdel, JD; Kachnic, LA; Langer, C; Peters, CA; Pugh, SL; Rabinovitch, RA; Ramalingam, A; Rashtian, A; Seider, MJ; Tomblyn, M; Wyatt, G	1
Chen, W; Huang, X; Lin, R; Wu, C; Wu, J; Zhang, X	1
Buller, J; Peters, F; Wenzel, C; Zinser, M; Zirk, M; Zöller, JE	1
Sartor, O	1
Atkinson, C; Attia, J; Christie, D; Delahunt, B; Denham, JW; Diamond, T; Duchesne, G; Gogna, NK; Joseph, D; Kenny, L; Lamb, DS; Matthews, J; Oldmeadow, C; Spry, NA; Steigler, A; Tai, KH; Turner, S	2
Chiarugi, P; Comito, G; Giannoni, E; Parri, M; Pietrovito, L; Taddei, ML	1
Aragon-Ching, JB; Finianos, A	1
Jayaram, R; Thavarajah, M	1
Chen, W; Huang, X; Jiang, H; Lin, R; Wu, C; Wu, J; Zhang, X; Zhu, B	1
Bjartell, A; Caris, C; Cicalese, V; Debruyne, F; Edenbrandt, L; Miller, K; Mulders, P; Ohlsson, M; Patel, A; Reza, M; Tammela, T; Thorsson, O; Trägårdh, E; Tubaro, A; Veiga, FG; Wirth, M; Witjes, W; Wollmer, P	1
Chouahnia, K; Culine, S; Fossey-Diaz, V; Guetz, GD; Landre, T; Taleb, C	1
Badalamenti, G; Bazan, V; Castellana, L; Galvano, A; Giuliana, G; Guadagni, F; Incorvaia, L; Pantano, F; Rizzo, S; Russo, A; Santini, D; Toia, F; Tonini, G; Vincenzi, B	1
Bismarck, E; Dörsam, J; Ebert, T; Schmitz-Dräger, BJ; Weiss, C	1
Fujimura, T; Homma, Y; Kume, H; Taguchi, S	1
Bastit, L; Guérif, S; Khemaies, S; Kouri, CE; Ktiouet, M; Lebret, T; Lortholary, A; Mouysset, JL; Murraciole, X	1
Bruzzese, F; Budillon, A; Capone, F; Caraglia, M; Carbone, C; Costantini, S; Di Gennaro, E; Leone, A; Milone, MR; Piro, G; Pucci, B	1
Coleman, RE; Fizazi, K; Galsky, MD; Gartrell, BA; Miller, K; Saad, F; Sternberg, CN	1
Alcaraz, A; Álvarez-Ossorio, JL; Anido, U; Bellmunt, J; Calderero, V; Carles, J; Comet-Batlle, J; Constela, M; Contreras, JA; de la Piedra, C; del Alba, AG; Delgado, D; Esteban, E; Fernández, JM; García-Escudero, A; Gómez-Caamano, A; Gómez-Veiga, F; González-Enguita, C; González-Gragera, B; Lara, PC; Lassa, A; Mahillo-Fernández, I; Mañas, A; Martín-Fernández, M; Martínez-Javaloyas, JM; Méndez, MJ; Meseguer, C; Morote, J; Murias, A; Quicios, C; Reynes, G; Ribal, MJ; Rodriguez, B; Rubio, G; Samper, P; San José, LA; Sánchez, E; Segarra, J; Solsona, E; Tabernero, AJ; Unda, M; Vázquez, F; Virizuela, JA	1
Becker, JT; Binkley, N; Buehring, B; Eickhoff, JC; Lang, JM; Liu, G; Malkovsky, M; McNeel, DG; Staab, MJ; Wallace, M; Wilding, G	1
Chen, H; Chen, W; Duan, F; Jin, H; Li, C; Liu, Q; Mo, L; Wang, F; Weng, Z; Yu, Z	1
Achel, DG; Alcaraz, M; Alcaraz-Saura, M; Olivares, A	1
Fujimoto, Y; Muramatsu, K; Murayama, M; Nakata, E; Nomura, T; Ogane, S; Sekine, R; Shibahara, T; Shibui, T; Uchiyama, T; Watanabe, A; Yakushiji, T; Yamamoto, N	1
Esa, A; Hara, I; Imanishi, M; Inagaki, T; Kajikawa, H; Kitagawa, M; Komura, T; Matsuyama, H; Nagao, K; Nishioka, T; Nozawa, M; Ogawa, T; Uejima, S; Uekado, Y; Uemura, H	1
Afonso, PD; Febbo, PG; Foye, A; George, DJ; Madden, JF; Morris, KK; Roy Choudhury, K; Spritzer, CE; Turnbull, JD; Vinson, EN	1
Clarke, NW	1
Arai, G; Fujimoto, N; Fukagai, T; Horie, S; Ide, H; Ikeda, D; Ishida, T; Kawaguchi, K; Kondo, Y; Mizokami, A; Namiki, M; Oh-Oka, H; Orito, M; Shimamura, M; Ueki, O; Ueno, S	1
Gore, E; Kachnic, LA; Kim, HE; Lawton, CA; Martin, AG; Nabid, A; Pugh, SL; Shah, AB; Smith, M; Tai, P	1
Fujimoto, N; Fukumoto, R; Hayashi, T; Koide, T; Oka, D; Soda, T	1
Hahn, NM; Kirkpatrick, K; Sharma, J; Sweeney, CJ; Yiannoutsos, CT	1
Arra, C; Bruzzese, F; Budillon, A; Caraglia, M; Chianese, MI; Ciardiello, C; Di Gennaro, E; Franco, R; Leone, A; Luciano, A; Milone, MR; Pucci, B; Rocco, M; Santini, D	1
Body, JJ	2
Brown, J; Fullarton, JR; Palmieri, C	1
Avvisati, G; Buscarini, M; Cicero, G; Di Cerbo, M; Flammia, G; Gregorj, C; Iuliani, M; Pantano, F; Rizzo, S; Russo, A; Santini, D; Sergi, F; Tonini, G; Vincenzi, B; Zamarchi, R; Zoccoli, A	1
D'Amico, AV	1
Balakumaran, A; Chung, K; Dodge, T; Edelsberg, J; Glass, AG; Lamerato, L; Lopez, A; Oster, G; Richert-Boe, KE; Richhariya, A; Wolff, GG	1
Abreu, A; Cohen, RJ; Denham, JW; Joseph, DJ; Kautto, A; Moseshvili, E; Spry, NA	1
Gerngroß, C; Hohlweg-Majert, B; Koerdt, S; Otto, S; Pautke, C; Ristow, M; Ristow, O; Schuster, R; Schwaiger, M	1
Atkinson, C; Ball, J; D'Este, C; Delahunt, B; Denham, JW; Diamond, T; Duchesne, G; Gogna, NK; Joseph, D; Kautto, A; Kenny, L; Lamb, DS; Lynch, K; Matthews, J; McElduff, P; Moscato, P; Murray, J; Nowitz, M; Rowan, D; Smart, R; Spry, NA; Steigler, A; Tai, KH; Turner, S; Vimieiro, R; Woodfield, R	1
Bhoopalam, N; Halabi, S; Hauke, RJ; Hussain, A; Kelly, WK; Monk, JP; Morris, M; Ryan, CJ; Saad, F; Sanford, B; Saylor, P; Small, EJ; Smith, MR; Stadler, W; Vogelzang, N	1
Caris, C; Cicalese, V; Debruyne, F; Delaere, K; Gomez Veiga, F; Huland, H; Lecouvet, F; Miller, K; Patel, A; Schulze, M; Tammela, T; Tubaro, A; Wirth, M; Witjes, W	1
Saad, F	9
Angelis, CD; Burke, N; Giotis, A; Goeree, R; Habib, M; Hopkins, RB; Pasetka, M; Xie, F	1
Geist, A; Grimm, M; Hoefert, S; Krimmel, M; Reinert, S; Sharghi, F	1
da Silva, DP; de Almeida, FC; de Araujo, ME; Marcucci, M; Marques, MM; Moreira, MS	1
Bouvet, M; Hayashi, K; Hiroshima, Y; Hoffman, RM; Kimura, H; Matsumoto, Y; Miwa, S; Sugimoto, N; Tsuchiya, H; Uehara, F; Yamamoto, M; Yamamoto, N; Yano, S; Zhang, Y	1
Croucher, PI; Eaton, CL; Fowles, CA; Holen, I; Meek, J; Ottewell, PD; Wang, N	1
Asaoka, H; Higaki, M; Higashihara, E; Kase, H; Matsumoto, T; Murata, A; Noda, H; Noda, K; Nutahara, K; Okegawa, T; Oshi, M; Tomoishi, J; Uchida, H	1
Froehner, M; Hakenberg, OW; Hölscher, T; Wirth, MP	1
Pautke, C; Ristow, O	1
Aparicio, A; Araujo, JC; Bilen, MA; Corn, PG; Fisch, MJ; Johnson, MM; Logothetis, CJ; Mathew, P; Pagliaro, LC; Tannir, NM; Tu, SM; Wong, FC	1
Gartrell, BA; Saad, F	1
Gao, AC; Ghosh, PM	1
Baamonde, A; Cal, S; Fernández-García, MT; Hidalgo, A; Lastra, A; Llorián-Salvador, M; Menéndez, L; Obaya, A; Pevida, M	1
Atmaca, H; Degirmenci, M; Karaca, B; Kisim, A; Sanli, UA; Sezgin, C; Uslu, R; Uzunoglu, S; Varol, U	1
Felsenberg, D; Gabbert, TI; Hoffmeister, B	1
Esa, A; Hara, I; Iki, M; Imanishi, M; Kajikawa, H; Komura, T; Matsuyama, H; Nagao, K; Nishioka, T; Nozawa, M; Ogawa, T; Uejima, S; Uekado, Y; Uemura, H	1
Arkko, S; Benzaïd, I; Clézardin, P; Määttä, JA; Mönkkönen, H; Mönkkönen, J; Räikkönen, J; Zlatev, HP	1
Hering, F; Imperio, M; Rodrigues, P	1
Bifulco, K; Bruzzese, F; Budillon, A; Carriero, MV; Ciardiello, C; Iannelli, F; Lombardi, R; Milone, MR; Pucci, B	1
Caraglia, M; D' Agostino, A; De Rosa, G; De Rosa, M; Gaito, O; Lamberti, M; Lusa, S; Porto, S; Schiraldi, C; Zappavigna, S	1
Bertelli, G; Jones, RM; Morgan, C	1
Atkinson, C; Attia, J; Delahunt, B; Denham, JW; Duchesne, G; Ebert, M; Gill, S; Gogna, NK; Haworth, A; Holliday, EG; Joseph, D; Kearvell, R; Kennedy, A; Kenny, L; Lamb, DS; Matthews, J; Murray, J; Oldmeadow, C; Spry, NA; Steigler, A; Tai, KH; Tan, H; Turner, S	1
Coleman, R; Efstathiou, E; Fizazi, K; Gartrell, BA; Logothetis, CJ; Saad, F; Sartor, O; Smith, MR; Sonpavde, G	1
Bienz, M; Saad, F	1
Belvedere, R; Bizzarro, V; Bruzzese, F; Budillon, A; Lombardi, R; Milone, MR; Parente, L; Petrella, A; Popolo, A; Pucci, B	1
Atkinson, C; Attia, J; Christie, D; Delahunt, B; Denham, JW; Duchesne, G; Egevad, L; Joseph, D; Matthews, J; Murray, JD; Spry, NA; Srigley, JR; Steigler, A	1
Arellano, J; Body, JJ; Braun, A; Brown, JE; Carducci, M; Diel, I; Fizazi, K; Fujiwara, Y; Karsh, L; Kueppers, F; Maniar, T; Martín, M; Paterson, A; Shore, N; Sieber, P; Stopeck, AT; Tonkin, K; Wang, H; Yardley, D	1
Bouvet, M; Hoffman, RM; Hu, C; Matsumoto, Y; Miwa, S; Nakanishi, H; Toneri, M; Yano, S; Zhang, Y; Zhao, M	1
Albiges, L; Burdett, S; Clarke, NW; Fisher, D; Fizazi, K; Gravis, G; James, ND; Mason, MD; Parmar, MKB; Rydzewska, LHM; Sweeney, CJ; Sydes, MR; Tierney, JF; Tombal, B; Vale, CL	1
Alzouebi, M; Amos, C; Attard, G; Beesley, S; Birtle, AJ; Brock, S; Cathomas, R; Chakraborti, P; Chowdhury, S; Clarke, NW; Cook, A; Cross, W; de Bono, J; Dearnaley, DP; Elliott, T; Gale, J; Gibbs, S; Graham, JD; Hetherington, J; Hughes, R; James, ND; Jones, RJ; Laing, R; Mason, MD; Matheson, D; McKinna, F; McLaren, DB; Millman, R; O'Sullivan, JM; Parikh, O; Parker, CC; Parmar, MK; Peedell, C; Protheroe, A; Ritchie, AW; Robinson, AJ; Russell, JM; Spears, MR; Srihari, N; Srinivasan, R; Staffurth, J; Sundar, S; Sydes, MR; Thalmann, G; Tolan, S; Tsang, D; Wagstaff, J	1
Andronis, L; Barton, D; Beesley, S; Billingham, LJ; Birtle, A; Brown, J; Chakraborti, P; Collins, S; Daunton, A; Goranitis, I; Hussain, S; James, ND; McLaren, D; O'Sullivan, J; Parker, C; Pirrie, SJ; Pope, AM; Porfiri, E; Russell, M; Staffurth, J; Stanley, A; Wylie, J	1
Ali, AA; Annett, S; Cunningham, R; Massey, AS; McBride, JW; McCaffrey, J; McCarthy, HO; McCrudden, CM; McErlean, EM; Migaud, ME; Pentlavalli, S; Redpath, P; Robson, T	1
Berruti, A; Bodei, S; Bonini, SA; Cristinelli, L; Fragni, M; Memo, M; Sigala, S; Simeone, C; Spano, PF; Stabile, A; Zani, D	1
Scher, HI	1
Chiarugi, P; Comito, G; Giannoni, E; Lanciotti, M; Morandi, A; Pons Segura, C; Serni, S; Taddei, ML	1
Sternberg, CN	1
Chang, B; Du, SX; Hu, QX; Li, XD; Lin, FX; Xie, D; Yu, GY; Zheng, GZ	1
Atkinson, C; Attia, J; Christie, D; Denham, JW; Duchesne, G; Holliday, EG; Joseph, D; Lamb, DS; Matthews, JH; Spry, NA; Sridharan, S; Steigler, A; Tai, KH	1
Deppe, H; Gschwend, JE; Hein, J; Kesting, MR; Mitchell, DA; Mücke, T; Retz, M; Thalgott, M; Wolff, KD	1
Egawa, S; Fujimoto, K; Kamba, T; Kamoto, T; Kawanishi, H; Kikuchi, T; Maruo, S; Masumori, N; Namiki, S; Narita, S; Ogawa, O; Okada, Y; Saito, H; Sakai, H; Sato, F; Satoh, T; Shimizu, Y; Sugimoto, M; Teishima, J; Terachi, T	1
Taneja, SS	1
Pinkawa, M	1
Fu, P; Li, Q; Wen, F; Yang, Y; Zhang, P	1
Foster, JC; Go, RS; Grubbs, SS; Himelstein, AL; Khatcheressian, JL; Loprinzi, CL; Novotny, PJ; O'Connor, T; O'Mara, A; Qin, R; Roberts, JD; Seisler, DK; Shapiro, CL; Velasco, MR; Weckstein, D	1
Alibhai, SMH; Emmenegger, U; Finelli, A; Hotte, SJ; Morgan, SC; Walker-Dilks, C; Winquist, E; Zukotynski, K	1
Dickow, B; Dobson, K; Heilbrun, LK; Lawhorn-Crews, JM; Shields, AF; Smith, D; Tehrani, OS; Vaishampayan, UN	1
Attard, G; Barber, J; Cassoly, E; Clarke, NW; Cross, W; Dearnaley, DP; Gilson, C; Ibrahim, A; James, ND; Jones, RJ; Logue, J; Lydon, A; Mason, MD; Matheson, D; Millman, R; Nikapota, AD; O'Sullivan, JM; Parker, CC; Parmar, MKB; Porfiri, E; Protheroe, A; Rentsch, CA; Ritchie, AWS; Russell, JM; Schiavone, F; Spears, MR; Srihari, NN; Sydes, MR; Thalmann, GN; Tsang, D; Wagstaff, J; Wallace, J; Walmsley, C	1
Joensuu, TK	1
Al-Nawas, B; Beck, J; Gamm, H; Grötz, KA; Thomas, C; Thüroff, JW; Wagner, W; Walter, C; Zinser, V	1
Abascal García, JM; Alcover García, J; Barreiro Mouro, A; Búcar Terrades, S; Carballido Rodriguez, J; Cózar Olmo, JM; Gálvez, R; Garcia-Galisteo, E; GómezVeiga, F; González Enguita, C; Jamardo Gonzalez, D; Luque Galvez, P; Medina López, RA; Minguez Martínez, RJ; Regadera Sejas, FJ; Rico Morales, M; Rodriguez Antolin, A; Sanchez Chapado, M; Sánchez Sánchez, E; Tabernero Gómez, AG	1
Asakura, T; Fujinami, K; Goto, A; Jinza, S; Okajima, K; Onuki, T; Senga, Y; Yamashita, Y	1
Amadori, D; Brigliadori, G; Carloni, S; Fabbri, F; Silvestrini, R; Tesei, A; Ulivi, P; Vannini, I; Zoli, W	1
Kyrgidis, A; Teleioudis, Z; Vahtsevanos, K	1
Barghout, V; Hatoum, HT; Lin, SJ; Lipton, A; Smith, MR	1
Anderson, J; Clarke, NW; Dearnaley, DP; Dwyer, J; James, ND; Mason, MD; Masters, J; Morgan, RC; Parmar, MK; Popert, RJ; Sanders, K; Stansfeld, J; Sydes, MR	2
Colombel, M	2
Berruti, A; Fusco, V; Ortega, C	1
Daignault, S; Dunn, RL; Escara-Wilke, J; Friedman, J; Ignatoski, KM; Keller, ET; Smith, DC; Zhang, X	1
Ariyoshi, N; Hosoi, A; Kakimi, K; Kondo, M; Nakagawa, K; Nakajima, J; Noguchi, A; Sakuta, K; Sato, K; Sato, S; Shiraishi, K; Yoshida, Y	1
Atmaca, H; Baran, Y; Cengiz, E; Erten, C; Gorumlu, G; Gul, MK; Karabulut, B; Karaca, B; Kucukzeybek, Y; Sanli, UA; Uslu, R; Uzunoglu, S	1
Haus, U; Jung, K; Lein, M; May, C; Miller, K; Schmidt, K; Schrader, M; Weissbach, L; Wirth, M	1
Balbay, MD; Serefoglu, EC	1
Kawashima, H; Kuratsukuri, K; Matsumura, K; Matsuyama, M; Nakatani, T; Ohnishi, K; Tanaka, T; Yoshimura, R	1
Baba, S; Bessho, H; Hayakawa, K; Ishiyama, H; Iwamura, M; Kimura, M; Matsumoto, K; Okusa, H; Satoh, T; Tabata, K	1
Clarke, NW; Dearnaley, DP; James, ND; Mason, MD; Morgan, RC; Parmar, MK; Royston, P; Sanders, K; Sydes, MR	1
Abbruzzese, A; Addeo, SR; Baldi, A; Budillon, A; Caraglia, M; Loeffler, M; Lupu, R; Marra, M; Meo, G; Rosolowski, M; Santini, D; Tonini, G; Vincenzi, B; Zappavigna, S	1
de Klerk, JM; Lam, MG; Zonnenberg, BA	1
Albiani, DA; Anderson, DP; Barton, JJ; Seth, A	1
Campbell-Baird, C; Costa, L; Demers, L; Harvey, H; Kim, C; Lipton, A	1
Atmaca, H; Cengiz, E; Erten, C; Gorumlu, G; Gul, MK; Karabulut, B; Karaca, B; Kucukzeybek, Y; Sanli, UA; Uslu, R; Uzunoglu, S	1
Clyburn, RD; Evans, CA; Holen, I; Lefley, DV; Reid, P	1
Arcenas, AG; Bhoopalam, N; Broderick, WR; Campbell, SC; Friedman, N; Garewal, H; Iyer, P; Moritz, T; Reda, D; Van Veldhuizen, PJ; Warren, S	1
Doggrell, SA	1
Gupta, NP; Nayyar, R; Sharma, N	1
Yuasa, T	1
Andreadis, CG; Antoniades, K; Boukovinas, I; Katodritou, E; Kitikidou, K; Koloutsos, GE; Kyrgidis, A; Paraskevopoulos, P; Teleioudis, Z; Triaridis, S; Vahtsevanos, K; Verrou, E; Zervas, K	1
Baziotis, N; Limouris, GS; Zafeirakis, A; Zissimopoulos, A	1
Saylor, PJ; Smith, MR	1
Crawford, BS; Kraut, EH; McNulty, RM; Turowski, RC	1
Parr, NJ; Wadhwa, VK; Weston, R	1
Dalle Carbonare, L; Donatelli, L; Giannini, S; Lo Cascio, V; Realdi, G; Valenti, MT	1
Baslé, MF; Blouin, S; Chappard, D; Libouban, H; Nyangoga, H	1
Abbruzzese, A; Addeo, R; Botti, G; Caraglia, M; Marra, M; Naviglio, S	1
Abrahamsson, PA; Miller, K; Saad, F	1
Endo, T; Ichikawa, T; Imamoto, T; Kamiya, N; Kawamura, K; Suzuki, H; Takano, M; Yano, M	1
Bossi, A; Chauchereau, A; Di Palma, M; Escudier, B; Fizazi, K; Gross-Goupil, M; Laplanche, A; Loriot, Y; Massard, C; Rajpar, S; Tournay, E	1
Bhoopalam, N; Campbell, SC; Ellis, NK; Friedman, N; Garewal, H; Iyer, P; Moritz, TE; Pandya, M; Reda, DJ; Thottapurathu, L; Vanveldhuizen, P; Warren, SR	1
Bornstein, MM; Frei, M; Iizuka, T; Reichart, PA; Schaller, B; Weimann, R	1
Atmaca, H; Karabulut, B; Karaca, B; Kisim, A; Sezgin, C; Uslu, R; Uzunoglu, S	1
Horvath, L; Nagrial, A	1
Hanamura, M; Iwamoto, T; Okuda, M; Soga, N; Sugimura, Y	1
Tan, WW	1
Lipton, A; Saad, F	3
Dai, J; Keller, ET; Keller, JM; Lu, Y; Mizokami, A; Yu, C; Zhang, J	1
Casey, R; Gesztesi, Z; Rochford, J	1
Chen, YM; Saad, F; Tchekmedyian, NS	1
Lee, RJ; Saylor, PJ; Smith, MR	1
Hering, F; Meler, A; Rodrigues, P	1
Ding, Y; Yang, L; Zhang, ZY; Zhou, LQ	1
Bochicchio, AM; Budillon, A; Caraglia, M; Catalano, A; Facchini, G; Ferrari, E; Gentilini, D; Iaffaioli, RV; Leopardo, D; Marra, L; Marra, M; Morabito, A; Nasti, G; Perrone, F; Piccirillo, MC; Striano, S; Tortoriello, A; Vitale, G	1
Fuji, K; Fukagai, T; Iwamoto, S; Morita, J; Naoe, M; Ogawa, Y; Shichijo, T; Takeshita, K; Terao, S	1
Eastham, J; Saad, F	2
Chan, J; Hui, RL; Schottinger, JE; Spence, MM	1
Fatatis, A; Liu, Q; Russell, MR	1
Aapro, M; Costa, L; Saad, F	1
Abbruzzese, A; Caraglia, M; De Rosa, G; La Rotonda, MI; Leonetti, C; Marra, M; Porru, M; Salzano, G; Zappavigna, S	1
Guo, A; Hatoum, HT; Lin, SJ; Lipton, A; Smith, MR	1
Missotten, G; Verheezen, Y	1
Fan, CP; Guo, A; Liu, J; Lu, M; Sharma, H; Shi, L; Velde, NV; Wu, EQ; Yu, AP	1
Albrecht, M; Jung, K; Lein, M; Miller, K; Wirth, M	1
Chen, HE; Chou, KY; Hwang, TI; Lin, JF; Lin, YC; Lin, YH; Tsai, TF	1
Baretton, GB; Benad, P; Erdmann, K; Fuessel, S; Goettsch, C; Hamann, C; Hofbauer, LC; Jakob, F; Rachner, TD; Rauner, M; Thiele, S; Wirth, MP	1
Morgan, GJ	1
Brown, J; Carducci, M; Damião, R; Dansey, R; Fizazi, K; Goessl, C; Jiang, Q; Karsh, L; Milecki, P; Rader, M; Shore, N; Smith, M; Tadros, S; Wang, H	1
Aragon-Ching, JB	1
Kamoto, T	1
Aoyama, M; Hirayama, Y; Ito, Y; Kanamaru, T; Kawamura, M; Nakamura, N; Sonoda, T	1
Koh, AJ; Li, X; Liao, J; McCauley, LK; Park, SI; Pienta, KJ; Rosol, TJ; Sadler, WD	1
Abbruzzese, A; Ascani, R; Calimeri, T; Caraglia, M; Cigliana, G; De Rosa, G; Franco, R; La Rotonda, MI; Leonetti, C; Liguori, G; Marra, M; Salzano, G; Scarsella, M; Tagliaferri, P; Tassone, P; Zappavigna, S	1
Botteman, MF; Carter, JA; Joshi, A; Kaura, S	1
Kakehi, Y; Kato, T; Kazuki, N; Kushida, Y; Kuwata, Y; Matsuoka, Y; Taoka, T; Yamamoto, N	1
Klatte, T; Kratzik, C; Remzi, M; Sinzinger, H; Waldert, M	1
Chan, CK; Hou, SM; Ng, CF; Wong, AY; Yee, CH; Yip, SK	1
Coleman, R	1
Itai, S; Izumi, K; Koh, E; Konaka, H; Maeda, Y; Miwa, S; Mizokami, A; Namiki, M; Shigehara, K; Shima, T	1
Chan, J; Hung, TT; Power, CA; Russell, PJ	1
Bauer, JS; Beck, N; Eitner, S; Kiefer, J; Stockmann, P; Wichmann, M	1
Hirata, H; Kanamaru, H; Kato, K; Nagahama, K; Yagibashi, Y; Yamamoto, M	1
Aktas, I; Atalay, B; Aybar, B; Cetin, O; Emes, Y; Issever, H; Mandel, NM; Oncu, B; Yalcin, S	1
Berenson, JR	1
Mulders, P; Saad, F	1
Koul, HK; Koul, S; Meacham, RB	1
Culine, S; Pouessel, D	1
Curi, MM; Lascala, CA; Marques, MM; Martins, MA; Martins, MD; Migliorati, CA; Tenis, CA	1
Culver, KW; Diener, M; Guo, A; Namjoshi, M; Parikh, K; Wu, EQ; Xie, J; Yu, AP	1
Higano, CS	3
Clézardin, P; Gnant, M	1
Endo, T; Ichikawa, T; Imamoto, T; Kamiya, N; Kawamura, K; Naoi, M; Nishimi, D; Suzuki, H; Takano, M; Yano, M	1
Ho, JW; Sundar, S	1
Chung, K; Cong, Z; Danese, M; Dansey, R; Halperin, M; Henry, D; Qian, Y; Rader, M; Stopeck, A	1
Gupta, SK; Reddy, SV	1
Barth, K; Bartsch, G; Blaheta, RA; Haferkamp, A; Juengel, E; Makarević, J; Mani, J; Vallo, S; Wiesner, C	1
Fujinami, K; Ikeda, I; Iwasaki, A; Kubota, Y; Noguchi, K; Noguchi, S; Uemura, H; Yanagisawa, M	1
Botteman, MF; Carter, JA; Joshi, AD; Kaura, S	1
Gross-Goupil, M; Pasticier, G; Ravaud, A; Roca, S	1
Berruti, A; Buttigliero, C; Coleman, RE; Cook, R; Lee, KA; Lipton, A; Saad, F; Smith, MR; Tampellini, M	1
Autio, KA; Morris, MJ; Scher, HI	1
Botteman, MF; Carter, JA	1
Enomoto, Y; Fujimura, T; Fukuhara, H; Hirano, Y; Homma, Y; Igawa, Y; Ishikawa, A; Kume, H; Miyazaki, H; Nishimatsu, H; Suzuki, M	1
Clezardin, P; Coleman, R; Gnant, M; Morgan, G	1
Coleman, RE	2
Ben Rhouma, S; Benrais, N; Cherif, K; Horchani, A; Sallami, S	1
Botteman, MF; Carter, JA; Kaura, S; Snedecor, SJ	1
Bishr, M; Saad, F	1
Atmaca, H; Cirak, Y; Karabulut, B; Karaca, B; Kisim, A; Sezgin, C; Uslu, R; Uzunoglu, S; Varol, U	1
Hashimoto, K; Hirata, K; Kitamura, H; Kobayashi, K; Maeda, T; Masumori, N; Tanaka, T; Tsukamoto, T	1
Carducci, MA; Paller, CJ; Philips, GK	1
Smith, MR	3
Penson, DF; Resnick, MJ	1
Morgans, AK; Smith, MR	1
Bulbul, MA; Elias, E; Farhat, FS; Khauli, RB; Saleh, A; Shamseddine, A	1
Nguyen, PL	1
Atkinson, C; Christie, D; Delahunt, B; Denham, JW; Duchesne, G; Gogna, NK; Joseph, D; Kenny, L; Lamb, DS; Matthews, J; McElduff, P; Spry, NA; Tai, KH; Turner, S; Wilcox, C	1
Armstrong, AJ; Fizazi, K; Freedland, S; Pienta, K; Saad, F; Saylor, PJ; Smith, MR; Tombal, B	1
Feng, JY; Wang, SJ; Wu, CQ; Zhang, P; Zheng, XH	1
Body, JJ; Brown, J; Coleman, R; Cook, R; Lipton, A; Smith, M	1
Gomez-Veiga, F; Martinez-Breijo, S; Morote, J; Planas, J; Ponce-Reixa, J	1
Bastit, L; El Kouri, C; Guérif, S; Ktiouet, M; Lebret, T; Lortholary, A; Mouysset, JL; Murraciole, X; Slimane, K	1
Garrett, Z; Jilani, A; Stevens, A; Sutcliffe, F	1
Datta, HK; Hanusch, B; Tuck, SP; Walker, J	1
Davies, M; Gates, J; Jo, M; Lee, YP; Lieberman, JR; Schwarz, EM; Wu, J; Zhang, X	1
Chen, B; Chin, JL; Gleason, DM; Goas, JA; Lacombe, L; Murray, R; Saad, F; Tchekmedyian, S; Venner, P; Vinholes, JJ	1
Gleason, D; Gordon, D; Kowalski, MO; Lipton, A; Reitsma, D; Rosen, L; Saad, F; Seaman, J; Small, E; Smith, M	1
Carducci, MA; Walczak, JR	1
Brown, LG; Corey, E; Higano, CS; Poot, M; Quinn, JE; Roudier, MP; Vessella, RL	1
Cook, R; Major, PP	1
Harland, SJ; Oosterlinck, W; Rosen, L	1
Benson, MC; Gilbert, SM; McKiernan, JM; Olsson, CA	1
Rosenthal, M	1
Angeli, A; Berruti, A; Dogliotti, L; Scarpa, RM; Terrone, C; Tucci, M	1
Atkins, CD	1
Gaines, KK	1
Kirby, RS	1
Eastham, J; Gleason, DM; Shasha, D; Smith, MR; Tchekmedyian, S; Zinner, N	1
Clarke, IA; Colston, KW; Kirby, RS; Oades, GM; Senaratne, SG	1
Khan, MA	1
Booth, B; Chen, G; Gobburu, JV; Hsieh, Y; Ibrahim, A; Leighton, J; Li, N; Pazdur, R; Rahman, A; Scher, N; Sridhara, R; Vause, D; Williams, G; Wood, R	1
Lin, SH; Logothetis, C; Tu, SM	1
Baldi, A; Santini, D; Scarpa, S; Tonini, G; Vincenzi, B	1
Heidenreich, A	1
Bankhead, C	1
Dearnaley, DP; Mason, MD; Moffat, LE; Naylor, SL; Parmar, MK; Powell, CS; Robinson, AC; Stott, M; Sydes, MR; Thompson, PM	1
Hohneker, J; Lacerna, L	1
Pitts, WR	1
Cameron, D	1
Saad, F; Schulman, CC	1
Fröhner, M; Hausmann, R; Wirth, M	1
Colston, KW; Coxon, JP; Kirby, RS; Oades, GM	2
Glendenning, GA; Radeva, JI; Reed, SD; Saad, F; Schulman, KA	1
Koutsilieris, M; Lembessis, P; Manoussakis, M; Sotiriou, E; Tenta, R; Tiblalexi, D	1
DeGrendele, H; Hightower, M; Klem, J	1
Maung, K	1
Breen, TL; Shane, E	1
Curley, T; Delacruz, A; Diani, M; Fallon, M; Fleisher, M; Flombaum, C; Kelly, WK; Morris, MJ; Scher, HI; Schwartz, L; Slovin, S; Smaletz, O; Solit, D; Zhu, A	1
Beer, TM; Garzotto, M; Tiffany, NM; Wersinger, EM	1
Hershman, D; Narayanan, R	1
Chin, JL; Gleason, DM; Goas, JA; Lacombe, L; Murray, R; Saad, F; Tchekmedyian, S; Venner, P; Vinholes, JJ; Zheng, M	1
Berry, S; Winquist, E	1
Brown, MD; Clarke, NW; George, NJ; Hart, CA; Montague, R; Ramani, VA	1
Abbou, CC; Allory, Y; Chopin, D; de la Taille, A; Hoznek, A; Paule, B; Salomon, L; Vacherot, F; Vordos, D; Yiou, R	1
Altundag, K; Altundag, O; Gunduz, M; Morandi, P	2
Coleman, RE; Evans, CA; Holen, I; Neville-Webbe, HL; Rostami-Hodjegan, A	1
Parker, CC	2
Price, N	1
Tanvetyanon, T	2
Decker, JL; Henderson, C; Hohneker, JA; Kaplan, BH; Lacerna, L; Orlowski, R; Purdy, MH; Schnell, FM; Vogel, CL; Wood, AJ; Yanagihara, RH	1
Brown, JE; Coleman, RE; Cook, RJ; Hei, YJ; Lee, KA; Lipton, A; Major, P; Saad, F; Smith, M; Zheng, M	1
Karakiewicz, P; Perrotte, P; Saad, F	1
Antoniou, N; Bamias, A; Bozas, G; Deliveliotis, C; Dimopoulos, MA; Efstathiou, E; Kastritis, E; Kostakopoulos, A; Papadimitriou, C; Skarlos, D	1
Algur, E; Häfeli, UO; Macklis, RM	1
Grenader, T; Peretz, T; Shavit, L; Uziely, B	1
Brahmbhatt, V; Patel, K; Ramu, V	1
Rexer, H	1
Kimura, S; Koizumi, M; Kuroda, J; Maekawa, T; Nogawa, M; Sato, K; Segawa, H; Yokota, A; Yuasa, T	1
Bilhartz, DL; Cook, R; Gittelman, MC; Goessl, C; Hei, YJ; Higano, CS; Hussain, A; Kabbinavar, F; Linnartz, R; Murray, R; Saad, F; Schulman, C; Small, EJ; Smith, MR; Wynne, C; Zheng, M; Zinner, NR	1
Fan, D; Fidler, IJ; He, J; Kim, SJ; Langley, RR; Mathew, P; Uehara, H; Yazici, S	1
Brown, LG; Corey, E; Keller, ET; Quinn, JE; Vessella, RL; Zhang, J	1
Arena, G; Bertelli, G; Botto, A; Colantonio, I; Fea, E; Garrone, O; Giubergia, S; Heouaine, A; Merlano, M; Occelli, M	1
Green, JR	1
Hellie, CM; Olson, KB; Pienta, KJ	1
Harmenberg, U; Hjelm-Eriksson, M; Kälkner, KM; Lennartsson, L; Lennernäs, B; Nilsson, S; Ullén, A	1
Avcu, F; Ural, AU	2
Katsouda, E; Mystakidou, K; Parpa, E; Vlahos, L	1
Broumand, V; Fortin, M; Marx, RE; Sawatari, Y	1
Conti, G	1
Rizzoli, R; Uebelhart, B	1
Koutsilieris, M; Lembessis, P; Luu-The, V; Sourla, A; Tenta, R	1
Barkley, CS; Bilhartz, DL; Given, RW; Julian, SR; Karlin, GS; Lacerna, LV; McWhorter, LT; Metzger, C; Polascik, TJ; Vestal, JC	1
Anagnostopoulos, A; Bamia, C; Bamias, A; Bozas, G; Dimopoulos, MA; Gika, D; Kastritis, E; Koutsoukou, V; Melakopoulos, I; Moulopoulos, LA; Papadimitriou, C; Terpos, E	1
Bianco, AR; Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; De Placido, S; Melisi, D; Tortora, G; Veneziani, BM	1
Arcara, C; Badalamenti, G; Casuccio, A; Cicero, G; Di Fede, G; Fulfaro, F; Gebbia, N; Intrivici, C; Leto, G; Rini, GB; Russo, A; Valerio, MR; Vitale, A	1
Brown, LG; Brubaker, KD; Corey, E; Vessella, RL	1
Klain, M; Liuzzi, R; Marinelli, A; Molino, L; Pace, L; Paone, G; Salvatore, M; Soricelli, A; Storto, G	1
Figg, WD; Macpherson, GR; Price, DK; Schimel, D; Singh, AS	1
Anstrom, KJ; Castel, LD; Saad, F; Schulman, KA; Weinfurt, KP	1
Faye, JC; Goffinet, M; Lajoie-Mazenc, I; Pradines, A; Séronie-Vivien, S; Thoulouzan, M; Weinbaum, C	1
Aglietta, M; Faggiuolo, R; Goia, F; Montemurro, F; Nanni, D; Ortega, C; Vormola, R	1
Budman, DR; Calabro, A	1
Djokic, M	1
Albers, P; Börgermann, C; Miller, K; Thüroff, J; Wirth, M	1
Colombel, M; Higano, CS; Mason, MD; Murray, R; Saad, F; Sartor, O; Schulman, C; Tubaro, A	1
Brown, J; Coleman, R; Cook, RJ; Hei, YJ; Lipton, A; Major, P; Saad, F; Smith, MR	2
Kantoff, P; Kaufman, DS; Michaelson, MD; Oh, WK; Smith, MR	1
Kawashima, H; Kuratsukuri, K; Nakatani, T; Sugimura, K; Tanaka, T	1
Beer, TM; Demers, LM; Huo, D; Lacerna, LV; Ryan, CW	1
Weingard, KK	1
Doyle-Lindrud, S	1
Fosså, SD; Hernes, E; Lilleby, W; Raabe, N; Waehre, H	1
Abbruzzese, A; Baldi, A; Bertieri, R; Budillon, A; Caraglia, M; D'Alessandro, AM; Leonetti, C; Marra, M; Meo, G; Santini, D; Tonini, G; Zupi, G	1
Igawa, M; Kikuno, N; Nakamura, S; Shiina, H; Urakami, S	1
Iguchi, H	1
Tombal, B	1
Adamus, AT; Sherer, JT	1
Anstrom, KJ; Castel, LD; DePuy, V; Saad, F; Schulman, KA; Weinfurt, KP	1
Kenna, T; Mattarollo, SR; Nicol, AJ; Nieda, M	1
Antràs, L; Daskivich, T; Duh, MS; Evan, C; Nakabayashi, M; Neary, MP; Oh, WK; Proctor, K; Smith, M; Tormey, LK	1
Altieri, V; Autorino, R; Benincasa, G; D'Armiento, M; De Placido, S; Di Lorenzo, G; Giordano, A; Giuliano, M; Morelli, E; Napodano, G; Russo, A	1
Eickenberg, HU; Haus, U; Jung, K; Lein, M; Loening, SA; Meissner, S; Miller, K; Schmidt, K; Stephan, C; Weissbach, L; Wirth, M	1
Brunelli, C; Campa, T; De Conno, F; Fagnoni, E; Giardina, V; Pigni, A; Ripamonti, C	1
Altieri, V; Autorino, R; Cancello, G; D'Armiento, M; De Laurentiis, M; De Placido, S; Di Lorenzo, G; Figg, WD; Imbimbo, C; Longo, N; Mirone, V; Perdonà, S; Tortora, G	1
Fallon, MA; Finkelstein, JS; Kantoff, PW; Kaufman, DS; Lee, H; McGovern, FJ; Michaelson, MD; Smith, MR	1
Salciccia, S; Sciarra, A	1
Dunn, RL; Gilbert, SM; Wei, JT	1
Afonso, Y; Bruna, P; Hering, FO; Meller, A; Rodrigues, P	1
Fantini, M; Nicoletti, S; Poggi, B; Possenti, C; Sartori, S; Tamburini, E; Tassinari, D	1
Bylow, K; Demers, LM; Henderson, TO; Huo, D; Ryan, CW; Stadler, WM; Vogelzang, NJ	1
Goldstein, HR; Gottesman, JE; Hull, GW; Israeli, RS; Lacerna, LV; Rosenberg, SJ; Saltzstein, DR; Tran, DN; Warsi, GM	1
Aglietta, M; Faggiuolo, R; Gilardino, MO; Goia, F; Montemurro, F; Nanni, D; Ortega, C; Vormola, R	1
Bertelli, G; Jones, RM; Leonard, RC; Lewis, PD; Morgan, C; Thomas, GA	1
Beer, TM; Davis, RL; Huo, D; McWhorter, LT; Ryan, CW; Stallings, JW	1
Bartoletti, R; Cai, T	1
Buccheri, S; Caccamo, N; Cicero, G; D'Asaro, M; Dieli, F; Eberl, M; Fulfaro, F; Gebbia, N; Hayday, AC; Meraviglia, S; Roberts, A; Salerno, A; Vermijlen, D	1
Crescimanno, M; Flandina, C; Leto, G; Tumminello, FM	1
Díaz Rubio, E; García Paredes, B; García Sáenz, JA; López Tarruella, S; Rodríguez Lajusticia, L; Villalobos, L	1
Chahine, GY; Farhat, FS; Ghosn, MG; Kattan, JG; Moukadem, WT; Nasr, FL; Yazbeck, NJ; Younes, FC	1
Bellomi, M; Bruschini, R; Cossu Rocca, M; Goldhirsch, A; Nole, F; Preda, L; Sanna, G; Verri, E	1
Aguilera Tubet, C; Ballestero Diego, R; Roca Edreira, A; Villanueva Peña, A; Zubillaga Guerrero, S	1
Chen, YM; Chin, J; Gleason, DM; Saad, F	1
Arlen, PM; Dahut, WL; Gulley, JL; Wu, S	1
Battaglia, S; Duteille, F; Gouin, F; Heymann, D; Heymann, MF; Lamoureux, F; Ory, B; Pilet, P; Redini, F	1
Beck, JF; Bumbul, B; Sonnemann, J	1
Copeman, M; Gurney, H; Rosenthal, MA; Woo, H; Zingarelli, G	1
Dahmane, A; de Klerk, JM; Lam, MG; Stevens, WH; van Rijk, PP; Zonnenberg, BA	1
Ahn, H; Cho, HY; Cho, KS; Chung, BH; Hong, SJ; Kim, CS	1
Miki, T; Okihara, K	1
Nishizawa, S; Sawada, Y; Yamauchi, T	1
McKeage, K; Plosker, GL	1
Eriksson, F; Pisa, P; Tsagozis, P	1
Brufsky, AM	1
Dhillon, S; Lyseng-Williamson, KA	1
Corey, E; Gross, TS; Morgan, TM; Pitts, TE; Poliachik, SL; Vessella, RL	1
Ichikawa, T; Imamoto, T; Kamiya, N; Kawamura, K; Suzuki, H	1
Badia, X; Chow, E; Costa, L; Lipton, A; Wardley, A	1
Badalamenti, G; D'Amico, C; Fulfaro, F; Incorvaia, L; Leto, G; Tumminello, FM	1
Fernandez, SA; Martin, CK; Nadella, MV; Pinzone, JJ; Rosol, TJ; Thudi, NK; Werbeck, JL	1
Berenson, J; Hortobagyi, G; Lipton, A; Major, PP	1
Boissier, S; Clézardin, P; Colombel, M; Delaissé, JM; Delmas, P; Ebetino, FH; Ferreras, M; Magnetto, S; Peyruchaud, O	1
Fong, EM; Guenette, RS; Lee, MV; Singer, FR	1

Reviews

91 review(s) available for zoledronic acid and Prostatic Neoplasms

Article	Year
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw. Current oncology (Toronto, Ont.), 2022, 03-05, Volume: 29, Issue:3 Topics: Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Humans; Male; Osteonecrosis; Prostatic Neoplasms; Zoledronic Acid	2022
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. The Cochrane database of systematic reviews, 2020, 12-03, Volume: 12 Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Denosumab; Diphosphonates; Etidronic Acid; Humans; Male; Network Meta-Analysis; Pamidronate; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Randomized Controlled Trials as Topic; RANK Ligand; Risedronic Acid; Zoledronic Acid	2020
The role of bone-targeted therapies for prostate cancer in 2017. Current opinion in supportive and palliative care, 2017, Volume: 11, Issue:3 Topics: Androstenes; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Male; Prospective Studies; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Zoledronic Acid	2017
Interventions for managing medication-related osteonecrosis of the jaw. The Cochrane database of systematic reviews, 2017, 10-06, Volume: 10 Topics: Angiogenesis Inhibitors; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Denosumab; Dental Care; Diphosphonates; Female; Humans; Hyperbaric Oxygenation; Imidazoles; Intercellular Signaling Peptides and Proteins; Jaw Diseases; Male; Oral Health; Osteonecrosis; Postoperative Complications; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Time Factors; Tooth Extraction; Zoledronic Acid	2017
Pharmacological interventions for the prevention of insufficiency fractures and avascular necrosis associated with pelvic radiotherapy in adults. The Cochrane database of systematic reviews, 2018, 04-23, Volume: 4 Topics: Adult; Androgen Antagonists; Bone Density Conservation Agents; Calcium Compounds; Diphosphonates; Femur Head Necrosis; Fractures, Stress; Humans; Imidazoles; Male; Pelvic Neoplasms; Prostatic Neoplasms; Radiation Injuries; Vitamin D; Vitamins; Zoledronic Acid	2018
What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis. Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 05-01, Volume: 29, Issue:5 Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Network Meta-Analysis; Prednisolone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid	2018
Effect of Diphosphonates on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer. Clinical genitourinary cancer, 2018, Volume: 16, Issue:6 Topics: Absorptiometry, Photon; Alendronate; Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Femur Neck; Humans; Lumbar Vertebrae; Male; Osteoporosis; Pelvic Bones; Prostatic Neoplasms; Zoledronic Acid	2018
Zoledronic acid for the treatment of prostate cancer. Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:6 Topics: Androgen Antagonists; Bone Neoplasms; Diphosphonates; Docetaxel; Humans; Male; Prostatic Neoplasms; Zoledronic Acid	2019
Effect of bisphosphonates on overall survival in subgroups of patients with prostate cancer. Clinical & experimental metastasis, 2019, Volume: 36, Issue:3 Topics: Bone Density; Bone Density Conservation Agents; Chemotherapy, Adjuvant; Clodronic Acid; Fractures, Bone; Humans; Male; Prostatic Neoplasms; Survival Rate; Zoledronic Acid	2019
Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis. Clinical genitourinary cancer, 2019, Volume: 17, Issue:4 Topics: Age Factors; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Male; Prostatic Neoplasms; Survival Analysis; Treatment Outcome; Zoledronic Acid	2019
How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials. Critical reviews in oncology/hematology, 2019, Volume: 142 Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Female; Humans; Male; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid	2019
Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer. European urology, 2014, Volume: 65, Issue:2 Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Fractures, Bone; Humans; Hypocalcemia; Imidazoles; Male; Molecular Targeted Therapy; Osteoclasts; Patient Selection; Prostatic Neoplasms; RANK Ligand; Risk Factors; Treatment Outcome; Zoledronic Acid	2014
[Inhibition of RANK ligand to treat bone metastases]. Bulletin du cancer, 2013, Volume: 100, Issue:11 Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Hypocalcemia; Imidazoles; Male; Multiple Myeloma; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid	2013
Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Dec-15, Volume: 19, Issue:24 Topics: Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Neoplasm Metastasis; Pamidronate; Prostatic Neoplasms; Zoledronic Acid	2013
Atraumatic tooth extraction in patients taking bisphosphonates: a review of literature and experience with three cases. Oral and maxillofacial surgery, 2014, Volume: 18, Issue:3 Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Elastomers; Female; Follow-Up Studies; Humans; Imidazoles; Male; Mandibular Diseases; Middle Aged; Orthodontic Appliances; Pancoast Syndrome; Prostatic Neoplasms; Retrospective Studies; Tooth Extraction; Zoledronic Acid	2014
Treatment of bone metastases in urologic malignancies. Urologia internationalis, 2014, Volume: 93, Issue:3 Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Cisplatin; Denosumab; Diphosphonates; Humans; Imidazoles; Male; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Prostatic Neoplasms; Quality of Life; Radiosurgery; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms; Zoledronic Acid	2014
Pathologic fracture in patients with metastatic prostate cancer. Current opinion in urology, 2014, Volume: 24, Issue:6 Topics: Androstenes; Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Pyridines; Radioisotopes; Radium; Zoledronic Acid	2014
Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options. European urology, 2015, Volume: 68, Issue:5 Topics: Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Prostatic Neoplasms; Radioisotopes; Radium; Zoledronic Acid	2015
Management of bone metastases in prostate cancer: a review. Current opinion in supportive and palliative care, 2015, Volume: 9, Issue:3 Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Quality of Life; Radioisotopes; Radiopharmaceuticals; Radium; Zoledronic Acid	2015
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. The Lancet. Oncology, 2016, Volume: 17, Issue:2 Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Disease-Free Survival; Docetaxel; Humans; Imidazoles; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Standard of Care; Survival Rate; Taxoids; Zoledronic Acid	2016
Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Survival Results From STAMPEDE (NCT00268476). Clinical advances in hematology & oncology : H&O, 2016, Volume: 14, Issue:4 Suppl 5 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Density Conservation Agents; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Diphosphonates; Humans; Imidazoles; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prostatic Neoplasms; Retreatment; Treatment Outcome; Zoledronic Acid	2016
Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours. European journal of cancer care, 2017, Volume: 26, Issue:6 Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Male; Orthopedic Procedures; Prostatic Neoplasms; Radiotherapy; Spinal Cord Compression; Zoledronic Acid	2017
Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline. Clinical oncology (Royal College of Radiologists (Great Britain)), 2017, Volume: 29, Issue:6 Topics: Absorptiometry, Photon; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Evidence-Based Medicine; Fractures, Bone; Humans; Imidazoles; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Randomized Controlled Trials as Topic; Zoledronic Acid	2017
Clinical efficacy and safety of zoledronic acid in prostate and breast cancer. Expert review of anticancer therapy, 2009, Volume: 9, Issue:9 Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid	2009
Bone health and prostate cancer. Prostate cancer and prostatic diseases, 2010, Volume: 13, Issue:1 Topics: Androgen Antagonists; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density; Bone Neoplasms; Clinical Trials as Topic; Denosumab; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Osteoclasts; Prostatic Neoplasms; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Zoledronic Acid	2010
Zoledronic acid: an unending tale for an antiresorptive agent. Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:1 Topics: Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Cell Line, Tumor; Diphosphonates; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Hydroxides; Imidazoles; Male; Oxides; Prostatic Neoplasms; Protein Prenylation; Zoledronic Acid	2010
Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates. BJU international, 2009, Volume: 104, Issue:11 Topics: Adult; Aged; Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Neoplasms, Hormone-Dependent; Osteoporosis; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid	2009
[Bone and Men's Health. Bisphosphonate therapy for prostate cancer]. Clinical calcium, 2010, Volume: 20, Issue:2 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Osteoporosis; Prostatic Neoplasms; Zoledronic Acid	2010
Bone-marker levels in patients with prostate cancer: potential correlations with outcomes. Current opinion in supportive and palliative care, 2010, Volume: 4, Issue:3 Topics: Alkaline Phosphatase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Collagen Type I; Denosumab; Diphosphonates; Disease Progression; Humans; Imidazoles; Male; Peptides; Prognosis; Prostatic Neoplasms; RANK Ligand; Risk Assessment; Treatment Outcome; Zoledronic Acid	2010
Treatment and prevention of bone complications from prostate cancer. Bone, 2011, Volume: 48, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Osteoblasts; Osteoclasts; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid	2011
Maintaining bone health in prostate cancer throughout the disease continuum. Seminars in oncology, 2010, Volume: 37 Suppl 1 Topics: Androgen Antagonists; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid	2010
Can bisphosphonates improve outcomes in patients with newly diagnosed multiple myeloma? Critical reviews in oncology/hematology, 2011, Volume: 77 Suppl 1 Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Breast Neoplasms; Clodronic Acid; Diphosphonates; Drug Evaluation, Preclinical; Female; Humans; Imidazoles; Male; Mice; Multiple Myeloma; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Treatment Outcome; Zoledronic Acid	2011
[Encounter of cancer cells with bone. Management of bone metastasis arising from prostate cancer]. Clinical calcium, 2011, Volume: 21, Issue:3 Topics: Antibodies, Monoclonal; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Evidence-Based Medicine; Humans; Imidazoles; Male; Molecular Targeted Therapy; NF-kappa B; Prostatic Neoplasms; Radioisotopes; Radium; Receptor Activator of Nuclear Factor-kappa B; Strontium; Zoledronic Acid	2011
New developments for treatment and prevention of bone metastases. Current opinion in oncology, 2011, Volume: 23, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Jaw; Male; Neoplasm Recurrence, Local; Osteonecrosis; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid	2011
Antitumor effects of bisphosphonates: from the laboratory to the clinic. Current opinion in supportive and palliative care, 2011, Volume: 5, Issue:3 Topics: Antineoplastic Agents; Apoptosis; Bone Density Conservation Agents; Breast Neoplasms; Cell Adhesion Molecules; Diphosphonates; Female; Humans; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Zoledronic Acid	2011
Bisphosphonate anticancer activity in prostate cancer and other genitourinary cancers. Anti-cancer agents in medicinal chemistry, 2012, Volume: 12, Issue:2 Topics: Animals; Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Prostate; Prostatic Neoplasms; Urogenital Neoplasms; Urogenital System; Zoledronic Acid	2012
New role for an established drug? Bisphosphonates as potential anticancer agents. Prostate cancer and prostatic diseases, 2012, Volume: 15, Issue:2 Topics: Animals; Antineoplastic Agents; Bone and Bones; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Clinical Trials as Topic; Diphosphonates; Drug Synergism; Female; Humans; Imidazoles; Male; Neoplasm Invasiveness; Neovascularization, Pathologic; Osteoclasts; Prostatic Neoplasms; Retrospective Studies; Zoledronic Acid	2012
Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. Cancer treatment reviews, 2012, Volume: 38, Issue:5 Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Disease-Free Survival; Drug Screening Assays, Antitumor; Female; Humans; Imidazoles; Male; Osteoclasts; Prostatic Neoplasms; Tumor Microenvironment; Zoledronic Acid	2012
Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours. PharmacoEconomics, 2012, Volume: 30, Issue:5 Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Carcinoma, Renal Cell; Cost-Benefit Analysis; Diphosphonates; Drug Costs; Europe; Health Care Costs; Humans; Imidazoles; Kidney Neoplasms; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Zoledronic Acid	2012
[Strategy in advanced castration-resistant prostate cancer]. Bulletin du cancer, 2012, Volume: 99 Suppl 1 Topics: Abiraterone Acetate; Androgen Antagonists; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Cancer Vaccines; Denosumab; Diphosphonates; Docetaxel; Estramustine; Humans; Imidazoles; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts; Zoledronic Acid	2012
Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer. Current treatment options in oncology, 2012, Volume: 13, Issue:2 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Denosumab; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Organometallic Compounds; Organophosphorus Compounds; Pain Management; Prostatic Neoplasms; Strontium; Zoledronic Acid	2012
Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancer. Expert review of pharmacoeconomics & outcomes research, 2012, Volume: 12, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Cost-Benefit Analysis; Denosumab; Diphosphonates; Drug Approval; Europe; Humans; Imidazoles; Male; Prostatic Neoplasms; United States; United States Food and Drug Administration; Zoledronic Acid	2012
Effects of bone-targeted agents on cancer progression and mortality. Journal of the National Cancer Institute, 2012, Jul-18, Volume: 104, Issue:14 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Disease Progression; Disease-Free Survival; Female; Goserelin; Humans; Imidazoles; Male; Menopause; Neoplasms; Prostatic Neoplasms; Survival Rate; Treatment Outcome; Zoledronic Acid	2012
Adjuvant bone-targeted therapy to prevent metastasis: lessons from the AZURE study. Current opinion in supportive and palliative care, 2012, Volume: 6, Issue:3 Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Male; Neoplasm Metastasis; Prostatic Neoplasms; Women's Health; Zoledronic Acid	2012
[The role of bisphosphonate in the treatment of bone metastases from prostate cancer]. La Tunisie medicale, 2012, Volume: 90, Issue:7 Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid	2012
Preventing bone complications in prostate cancer. Current opinion in supportive and palliative care, 2012, Volume: 6, Issue:3 Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Life Style; Male; Prostatic Neoplasms; Selective Estrogen Receptor Modulators; Zoledronic Acid	2012
Management of bone metastases in refractory prostate cancer--role of denosumab. Clinical interventions in aging, 2012, Volume: 7 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Neoplasms; Denosumab; Diphosphonates; Disease-Free Survival; Humans; Hypocalcemia; Imidazoles; Male; Orchiectomy; Osteonecrosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; RANK Ligand; Zoledronic Acid	2012
Quality of life with advanced metastatic prostate cancer. The Urologic clinics of North America, 2012, Volume: 39, Issue:4 Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Denosumab; Diphosphonates; Disease Progression; Docetaxel; Health Status Indicators; Humans; Imidazoles; Male; Mitoxantrone; Prostatic Neoplasms; Quality of Life; Taxoids; Treatment Outcome; Zoledronic Acid	2012
Bone-targeted agents: preventing skeletal complications in prostate cancer. The Urologic clinics of North America, 2012, Volume: 39, Issue:4 Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Bone Density; Bone Neoplasms; Clinical Trials as Topic; Clodronic Acid; Denosumab; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Osteoclasts; Osteoporosis; Pamidronate; Prostatic Neoplasms; Quality of Life; Samarium; Toremifene; Zoledronic Acid	2012
New and emerging therapies for bone metastases in genitourinary cancers. European urology, 2013, Volume: 63, Issue:2 Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Kidney Neoplasms; Male; Prospective Studies; Prostatic Neoplasms; Radiopharmaceuticals; Radium; Randomized Controlled Trials as Topic; RANK Ligand; Urinary Bladder Neoplasms; Urogenital Neoplasms; Urothelium; Zoledronic Acid	2013
Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition. Actas urologicas espanolas, 2013, Volume: 37, Issue:5 Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Clinical Trials, Phase III as Topic; Denosumab; Diphosphonates; Double-Blind Method; Forecasting; Fractures, Spontaneous; Humans; Imidazoles; Male; Models, Biological; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoplasm Proteins; Practice Guidelines as Topic; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Zoledronic Acid	2013
The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer investigation, 2002, Volume: 20 Suppl 2 Topics: Adenocarcinoma; Biomarkers; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Osteoclasts; Osteolysis; Osteoporosis; Pain; Pamidronate; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Safety; Zoledronic Acid	2002
Pharmacological treatments for prostate cancer. Expert opinion on investigational drugs, 2002, Volume: 11, Issue:12 Topics: Antibodies, Monoclonal; Atrasentan; Dendritic Cells; Diphosphonates; Genetic Therapy; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Imidazoles; Male; Microtubules; Prostatic Neoplasms; Pyrrolidines; Radiopharmaceuticals; Zoledronic Acid	2002
Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. American journal of clinical oncology, 2002, Volume: 25, Issue:6 Suppl 1 Topics: Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Data Interpretation, Statistical; Diphosphonates; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Male; Models, Statistical; Pain; Pamidronate; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid	2002
Broad clinical activity of zoledronic acid in osteolytic to osteoblastic bone lesions in patients with a broad range of solid tumors. American journal of clinical oncology, 2002, Volume: 25, Issue:6 Suppl 1 Topics: Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Prostatic Neoplasms; Zoledronic Acid	2002
The role of intravenous zoledronic acid in the management of high-risk prostate cancer. Current opinion in urology, 2003, Volume: 13, Issue:2 Topics: Animals; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Injections, Intravenous; Male; Palliative Care; Prostatic Neoplasms; Risk Factors; Zoledronic Acid	2003
Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid. Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 21 Topics: Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Diphosphonates; Humans; Imidazoles; Male; Palliative Care; Prostatic Neoplasms; Zoledronic Acid	2002
[The role of bisphosphonates in the treatment of bone metastases from urogenital cancer ]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2003, Volume: 13, Issue:2 Suppl 1 Topics: Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Kidney Neoplasms; Male; Molecular Structure; Prostatic Neoplasms; Urogenital Neoplasms; Zoledronic Acid	2003
Bisphosphonates in the management of metastatic prostate cancer. Oncology, 2003, Volume: 65 Suppl 1 Topics: Antineoplastic Agents; Bone Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Male; Pain; Palliative Care; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid	2003
Bisphosphonates to prevent skeletal complications in men with metastatic prostate cancer. The Journal of urology, 2003, Volume: 170, Issue:6 Pt 2 Topics: Analgesics, Non-Narcotic; Antimetabolites; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Retrospective Studies; Zoledronic Acid	2003
Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors. Seminars in oncology, 2003, Volume: 30, Issue:5 Suppl 16 Topics: Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Multiple Myeloma; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Zoledronic Acid	2003
Proven efficacy of zoledronic acid in the treatment of bone metastases in patients with breast cancer and other malignancies. Breast (Edinburgh, Scotland), 2003, Volume: 12 Suppl 2 Topics: Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Osteolysis; Prognosis; Prostatic Neoplasms; Survival Analysis; Treatment Outcome; United Kingdom; Zoledronic Acid	2003
Role of bisphosphonates in prostate cancer. European urology, 2004, Volume: 45, Issue:1 Topics: Androgen Antagonists; Bone Neoplasms; Diphosphonates; Forecasting; Humans; Imidazoles; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Zoledronic Acid	2004
Advances in the use of bisphosphonates in the prostate cancer setting. Prostate cancer and prostatic diseases, 2004, Volume: 7, Issue:2 Topics: Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid	2004
Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone. Clinical prostate cancer, 2002, Volume: 1, Issue:3 Topics: Bone Neoplasms; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Palliative Care; Prostatic Neoplasms; Zoledronic Acid	2002
Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer. Current oncology reports, 2004, Volume: 6, Issue:4 Topics: Absorptiometry, Photon; Alendronate; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Calcitonin; Calcium; Clodronic Acid; Diphosphonates; Drug Therapy, Combination; Estrogens; Etidronic Acid; Female; Humans; Imidazoles; Male; Osteoporosis; Prostatic Neoplasms; Quality of Life; Risedronic Acid; Risk Factors; Treatment Outcome; Vitamin D; Zoledronic Acid	2004
Osteoclast-targeted therapy for prostate cancer. Current treatment options in oncology, 2004, Volume: 5, Issue:5 Topics: Adult; Aged; Androgens; Bone Density; Bone Neoplasms; Diphosphonates; Drug Resistance, Neoplasm; Fractures, Bone; Humans; Imidazoles; Male; Middle Aged; Osteoclasts; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Zoledronic Acid	2004
Benefit of extended zoledronate therapy for patients with bone metastases from hormone-refractory prostate cancer. Clinical prostate cancer, 2004, Volume: 3, Issue:2 Topics: Adult; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Imidazoles; Male; Middle Aged; Neoplasm Staging; Prognosis; Prostatic Neoplasms; Risk Assessment; Survival Analysis; Treatment Outcome; Zoledronic Acid	2004
The role of bisphosphonates in hormone-refractory prostate cancer. World journal of urology, 2005, Volume: 23, Issue:1 Topics: Antineoplastic Agents; Bone Density; Bone Neoplasms; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid	2005
The role of bisphosphonates in the treatment of prostate cancer. BJU international, 2005, Volume: 95, Issue:7 Topics: Androgen Antagonists; Bone Neoplasms; Clinical Trials, Phase III as Topic; Clodronic Acid; Diphosphonates; Forecasting; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid	2005
Current status of treatment for patients with metastatic prostate cancer. The Canadian journal of urology, 2005, Volume: 12 Suppl 2 Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Neoplasms; Creatinine; Diphosphonates; Docetaxel; Drug Monitoring; Humans; Imidazoles; Male; Prostatic Neoplasms; Taxoids; Zoledronic Acid	2005
Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates. Acta oncologica (Stockholm, Sweden), 2005, Volume: 44, Issue:3 Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Bone Density; Bone Diseases; Bone Neoplasms; Diphosphonates; Disease Models, Animal; Humans; Imidazoles; Male; Osteolysis; Prostatic Neoplasms; Tumor Burden; Zoledronic Acid	2005
Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid. Urology, 2005, Volume: 66, Issue:3 Topics: Adenocarcinoma; Androgen Antagonists; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Prostatic Neoplasms; Treatment Failure; Zoledronic Acid	2005
Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU international, 2005, Volume: 96, Issue:7 Topics: Aged; Bone Neoplasms; Bone Resorption; Diphosphonates; Female; Humans; Imidazoles; Kidney Neoplasms; Male; Middle Aged; Pain; Prostatic Neoplasms; Zoledronic Acid	2005
[Zoledronic acid in the treatment of prostate cancer]. Minerva urologica e nefrologica = The Italian journal of urology and nephrology, 2005, Volume: 57, Issue:4 Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid	2005
The role of bisphosphonates in the management of prostate cancer. Current oncology reports, 2006, Volume: 8, Issue:3 Topics: Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Medical Oncology; Orchiectomy; Prostatic Neoplasms; Survival; Zoledronic Acid	2006
Zometa in the treatment of diseminated prostate cancer. Acta chirurgica Iugoslavica, 2005, Volume: 52, Issue:4 Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid	2005
[Therapeutic options for hormone-refractory prostate cancer]. Der Urologe. Ausg. A, 2006, Volume: 45, Issue:5 Topics: Androgen Antagonists; Antineoplastic Agents; Clinical Trials as Topic; Diphosphonates; Docetaxel; Drug Resistance, Neoplasm; Humans; Imidazoles; Male; Practice Patterns, Physicians'; Prostatic Neoplasms; Taxoids; Zoledronic Acid	2006
The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel. Clinical genitourinary cancer, 2006, Volume: 4, Issue:4 Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Practice Guidelines as Topic; Prostatic Neoplasms; Zoledronic Acid	2006
Nursing implications of androgen deprivation therapy-associated bone loss. Urologic nursing, 2006, Volume: 26, Issue:4 Topics: Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Calcium, Dietary; Diphosphonates; Exercise Therapy; Fractures, Bone; Health Promotion; Humans; Imidazoles; Life Style; Male; Morbidity; Nurse's Role; Nursing Assessment; Osteoporosis; Patient Education as Topic; Prostatic Neoplasms; Risk Factors; Vitamin D; Zoledronic Acid	2006
Implications of androgen-deprivation therapy in patients with prostate cancer: A case study. Clinical journal of oncology nursing, 2006, Volume: 10, Issue:5 Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Combined Modality Therapy; Diphosphonates; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Jaw Diseases; Leuprolide; Male; Orchiectomy; Osteonecrosis; Osteoporosis; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, Conformal; Risk Factors; Tomography, X-Ray Computed; Zoledronic Acid	2006
[Treatment of hormone-resistant prostate cancer]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2006, Nov-02, Volume: 126, Issue:21 Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Decompression, Surgical; Diphosphonates; Docetaxel; Drug Resistance, Neoplasm; Humans; Imidazoles; Male; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Zoledronic Acid	2006
[Molecular mechanism and potential targets for bone metastasis]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:1 Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Male; Mice; Mice, Nude; Neoplastic Cells, Circulating; Osteolysis; Parathyroid Hormone-Related Protein; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid	2007
New research findings on zoledronic acid: survival, pain, and anti-tumour effects. Cancer treatment reviews, 2008, Volume: 34, Issue:2 Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Pain; Prostatic Neoplasms; Urogenital Neoplasms; Zoledronic Acid	2008
[Therapeutic guidelines in prostate cancer and role for bisphosphonates in bone metastasis]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Nov-28, Volume: 65 Suppl 9 Topics: Androgen Antagonists; Antineoplastic Agents; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Docetaxel; Drug Therapy, Combination; Humans; Imidazoles; Male; Osteoporosis; Practice Guidelines as Topic; Prognosis; Prostatectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Zoledronic Acid	2007
Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases. PharmacoEconomics, 2008, Volume: 26, Issue:3 Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Lung Neoplasms; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Quality-Adjusted Life Years; Zoledronic Acid	2008
Cancer treatment-induced bone loss: pathophysiology and clinical perspectives. The oncologist, 2008, Volume: 13, Issue:2 Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Male; Osteoporosis; Prostatic Neoplasms; Zoledronic Acid	2008
Zoledronic acid : a review of its use in the management of bone metastases of malignancy. Drugs, 2008, Volume: 68, Issue:4 Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Male; Multiple Myeloma; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Zoledronic Acid	2008
[Bony lesion with prostate cancer]. Clinical calcium, 2008, Volume: 18, Issue:4 Topics: Antibodies, Monoclonal; Azepines; Bone Neoplasms; Cathepsin K; Cathepsins; Diphosphonates; Enzyme Inhibitors; Humans; Imidazoles; Male; Matrix Metalloproteinases; Osteoclasts; Osteolysis; Osteoporosis; Parathyroid Hormone-Related Protein; Prostatic Neoplasms; RANK Ligand; Sulfones; Zoledronic Acid	2008
Impact of skeletal complications on patients' quality of life, mobility, and functional independence. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2008, Volume: 16, Issue:8 Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Health Status; Humans; Imidazoles; Male; Pain; Prostatic Neoplasms; Quality of Life; Zoledronic Acid	2008
Oral bisphosphonates: A review of clinical use in patients with bone metastases. Cancer, 2000, Jan-01, Volume: 88, Issue:1 Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid	2000

Trials

98 trial(s) available for zoledronic acid and Prostatic Neoplasms

Article	Year
Impact of Zoledronic Acid and Denosumab Treatment on Growth Factor Concentration in Platelet Rich Fibrin of Patients With Osteolytic Bone Metastases. Anticancer research, 2021, Volume: 41, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Female; Humans; Intercellular Signaling Peptides and Proteins; Leukocyte Count; Male; Middle Aged; Osteolysis; Platelet Count; Platelet-Rich Fibrin; Prostatic Neoplasms; Young Adult; Zoledronic Acid	2021
Risk factors of skeletal-related events in patients with bone metastatic castration-resistant prostate cancer undergoing treatment with zoledronate. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022, Volume: 30, Issue:2 Topics: Aged; Bone and Bones; Bone Neoplasms; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Risk Factors; Zoledronic Acid	2022
Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic. Journal of medical economics, 2017, Volume: 20, Issue:8 Topics: Bone Density Conservation Agents; Bone Diseases; Breast Neoplasms; Cost-Benefit Analysis; Czech Republic; Denosumab; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Male; Markov Chains; Models, Econometric; Neoplasms; Prostatic Neoplasms; Quality of Life; Quality-Adjusted Life Years; Zoledronic Acid	2017
Association between measures of treatment quality and disease progression in prostate cancer radiotherapy: An exploratory analysis from the TROG 03.04 RADAR trial. Journal of medical imaging and radiation oncology, 2018, Volume: 62, Issue:2 Topics: Adult; Aged; Androgen Antagonists; Australia; Combined Modality Therapy; Diphosphonates; Disease Progression; Humans; Imidazoles; Male; Middle Aged; New Zealand; Prostatic Neoplasms; Radiotherapy Dosage; Survival Rate; Zoledronic Acid	2018
Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial. Annals of nuclear medicine, 2018, Volume: 32, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Osteoblasts; Palliative Care; Prostatic Neoplasms; Quality of Life; Radiopharmaceuticals; Safety; Survival Analysis; Zoledronic Acid	2018
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, The Lancet. Oncology, 2019, Volume: 20, Issue:2 Topics: Aged; Androgen Antagonists; Australia; Brachytherapy; Cause of Death; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; New Zealand; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment; Survival Analysis; Time Factors; Treatment Outcome; Zoledronic Acid	2019
Automated Bone Scan Index as an Imaging Biomarker to Predict Overall Survival in the Zometa European Study/SPCG11. European urology oncology, 2021, Volume: 4, Issue:1 Topics: Artificial Intelligence; Biomarkers; Bone Density; Bone Neoplasms; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Survival Rate; Zoledronic Acid	2021
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study. British journal of cancer, 2013, Jun-25, Volume: 108, Issue:12 Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Diphosphonates; Disease Progression; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Predictive Value of Tests; Prognosis; Prostatic Neoplasms; Risk Factors; Survival Analysis; Zoledronic Acid	2013
A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy. Clinical genitourinary cancer, 2013, Volume: 11, Issue:4 Topics: Aged; Alkaline Phosphatase; Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Cell Proliferation; Diphosphonates; Drug Administration Schedule; Goserelin; Humans; Imidazoles; Leuprolide; Lymphocyte Count; Male; Middle Aged; Osteoporosis; Prostate-Specific Antigen; Prostatic Neoplasms; T-Lymphocytes; Zoledronic Acid	2013
Comparison between zoledronic acid and clodronate in the treatment of prostate cancer patients with bone metastases. Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:3 Topics: Aged; Bone Density; Bone Neoplasms; Clodronic Acid; Diphosphonates; Disease-Free Survival; Humans; Imidazoles; Male; Prospective Studies; Prostatic Neoplasms; Survival Rate; Zoledronic Acid	2013
Phase II trial of zoledronic acid combined with androgen-deprivation therapy for treatment-naïve prostate cancer with bone metastasis. International journal of clinical oncology, 2014, Volume: 19, Issue:4 Topics: Aged; Androgen Antagonists; Androgens; Bone Neoplasms; Diphosphonates; Disease-Free Survival; Goserelin; Humans; Imidazoles; Male; Middle Aged; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid	2014
Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castration-resistant prostate cancer--factors affecting diagnostic success. Radiology, 2013, Volume: 269, Issue:3 Topics: Biopsy; Bone Density Conservation Agents; Bone Marrow; Diphosphonates; Everolimus; Gene Expression Profiling; Humans; Imidazoles; Immunosuppressive Agents; Male; Prostatic Neoplasms; RNA; Sirolimus; Tomography, X-Ray Computed; Ultrasonography, Interventional; Zoledronic Acid	2013
Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study. Anticancer research, 2013, Volume: 33, Issue:9 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Prostatic Neoplasms; Zoledronic Acid	2013
RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients. Prostate cancer and prostatic diseases, 2013, Volume: 16, Issue:4 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Osteoporosis; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid	2013
Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event. Clinical genitourinary cancer, 2014, Volume: 12, Issue:1 Topics: Aged; Alkaline Phosphatase; Amino Acids; Androgen Antagonists; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Remodeling; Denosumab; Diphosphonates; Disease Progression; Disease-Free Survival; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Osteocalcin; Pamidronate; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid	2014
Zoledronic acid induces a significant decrease of circulating endothelial cells and circulating endothelial precursor cells in the early prostate cancer neoadjuvant setting. Oncology, 2013, Volume: 85, Issue:6 Topics: Aged; Angiogenesis Inhibitors; Bone Density Conservation Agents; Cell Movement; Diphosphonates; Endothelial Cells; Humans; Imidazoles; Male; Middle Aged; Neoadjuvant Therapy; Prostatic Neoplasms; Stem Cells; Zoledronic Acid	2013
Serum procollagen 1 amino-terminal propeptide (P1NP) in prostate cancer: pitfalls of its use as an early surrogate marker for bone metastasis. Journal of medical imaging and radiation oncology, 2014, Volume: 58, Issue:4 Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Drug Therapy, Combination; Early Detection of Cancer; Humans; Imidazoles; Leuprolide; Male; Middle Aged; New South Wales; Peptide Fragments; Prevalence; Procollagen; Prostatic Neoplasms; Reproducibility of Results; Risk Factors; Sensitivity and Specificity; Survival Rate; Treatment Outcome; Zoledronic Acid	2014
Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced pr BJU international, 2014, Volume: 114, Issue:3 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Australia; Bone Density; Bone Density Conservation Agents; Diphosphonates; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; New Zealand; Prostatic Neoplasms; Spinal Fractures; Treatment Outcome; Zoledronic Acid	2014
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Apr-10, Volume: 32, Issue:11 Topics: Adenocarcinoma; Aged; Androgen Antagonists; Bone Density Conservation Agents; Bone Neoplasms; Diagnostic Imaging; Diphosphonates; Disease Progression; Humans; Imidazoles; Male; Orchiectomy; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid	2014
Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS). European urology, 2015, Volume: 67, Issue:3 Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Chi-Square Distribution; Diphosphonates; Drug Administration Schedule; Europe; Humans; Imidazoles; Kallikreins; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Neoplasm Grading; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Time Factors; Treatment Failure; Zoledronic Acid	2015
Zoledronic acid improves clinical outcomes in patients with bone metastatic hormone-naïve prostate cancer in a multicenter clinical trial. Anticancer research, 2014, Volume: 34, Issue:8 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Collagen Type I; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Peptides; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid	2014
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial The Lancet. Oncology, 2014, Volume: 15, Issue:10 Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Brachytherapy; Combined Modality Therapy; Diphosphonates; Disease-Free Survival; Drug Administration Schedule; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Treatment Outcome; Zoledronic Acid	2014
Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer, 2015, Jan-01, Volume: 121, Issue:1 Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Doxorubicin; Humans; Imidazoles; Male; Prostatic Neoplasms; Strontium Radioisotopes; Survival Analysis; Treatment Outcome; Zoledronic Acid	2015
Significance of baseline bone markers on disease progression and survival in hormone-sensitive prostate cancer with bone metastasis. World journal of urology, 2015, Volume: 33, Issue:9 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alkaline Phosphatase; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Diphosphonates; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Therapy, Combination; Follow-Up Studies; Goserelin; Humans; Imidazoles; Japan; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Survival Rate; Time Factors; Tosyl Compounds; Zoledronic Acid	2015
Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2015, Volume: 115, Issue:3 Topics: Aged; Androgen Antagonists; Brachytherapy; Chemoradiotherapy; Diphosphonates; Humans; Imidazoles; Male; Neoplasm Staging; Prostatic Neoplasms; Radiotherapy Dosage; Treatment Outcome; Urethral Stricture; Zoledronic Acid	2015
Validation of International Society of Urological Pathology (ISUP) grading for prostatic adenocarcinoma in thin core biopsies using TROG 03.04 'RADAR' trial clinical data. Pathology, 2015, Volume: 47, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Androgen Antagonists; Antineoplastic Agents; Biopsy, Large-Core Needle; Chemoradiotherapy; Consensus Development Conferences as Topic; Diphosphonates; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Pathology, Surgical; Proportional Hazards Models; Prostatic Neoplasms; Societies, Medical; Urology; Zoledronic Acid	2015
Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016, Volume: 24, Issue:1 Topics: Administration, Cutaneous; Aged; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Imidazoles; Infusions, Intravenous; Long-Term Care; Male; Middle Aged; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid	2016
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet (London, England), 2016, Mar-19, Volume: 387, Issue:10024 Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Diphosphonates; Disease Progression; Docetaxel; Drug Administration Schedule; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids; Treatment Outcome; Zoledronic Acid	2016
Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial. JAMA oncology, 2016, Volume: 2, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Diphosphonates; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Prostatic Neoplasms; Strontium; Taxoids; Zoledronic Acid	2016
Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2016, Volume: 121, Issue:1 Topics: Aged; Androgen Antagonists; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Disease Progression; Humans; Imidazoles; Male; Middle Aged; Prognosis; Prostatic Neoplasms; Radiosurgery; Zoledronic Acid	2016
Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - A prospective study over 6 years. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery, 2016, Volume: 44, Issue:10 Topics: Aged; Aged, 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Prostatic Neoplasms; Radiography, Panoramic; Risk Factors; Tomography, X-Ray Computed; Zoledronic Acid	2016
A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial. International journal of clinical oncology, 2017, Volume: 22, Issue:1 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Disease-Free Survival; Follow-Up Studies; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Time Factors; Treatment Failure; Zoledronic Acid	2017
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA, 2017, 01-03, Volume: 317, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Pain Measurement; Prostatic Neoplasms; Sample Size; Spinal Cord Compression; Spinal Fractures; Zoledronic Acid	2017
A Pilot Trial Evaluating Zoledronic Acid Induced Changes in [ Molecular imaging and biology, 2017, Volume: 19, Issue:6 Topics: Aged; Arabinofuranosyluracil; Biomarkers, Tumor; Bone Neoplasms; Bone Remodeling; Diphosphonates; Fluorine Radioisotopes; Humans; Image Processing, Computer-Assisted; Imidazoles; Male; Middle Aged; Pilot Projects; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Reproducibility of Results; Tomography, X-Ray Computed; Zoledronic Acid	2017
Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, May-10, Volume: 35, Issue:14 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Celecoxib; Diphosphonates; Disease-Free Survival; Early Termination of Clinical Trials; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Lymphatic Metastasis; Male; Middle Aged; Orchiectomy; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Time Factors; Zoledronic Acid	2017
[Effectiveness and tolerability of zoledronic acid in the treatment of metastatic prostate cancer]. Actas urologicas espanolas, 2008, Volume: 32, Issue:5 Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Pain; Prospective Studies; Prostatic Neoplasms; Zoledronic Acid	2008
Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial. BJU international, 2009, Volume: 103, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Pyrazoles; Risk Factors; Sulfonamides; Taxoids; Treatment Outcome; Zoledronic Acid	2009
Change in markers of bone metabolism with chemotherapy for advanced prostate cancer: interleukin-6 response is a potential early indicator of response to therapy. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2009, Volume: 29, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Docetaxel; Estramustine; Humans; Imidazoles; Interleukin-6; Male; Middle Aged; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Zoledronic Acid	2009
Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid. The Prostate, 2009, May-01, Volume: 69, Issue:6 Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Collagen Type I; Diphosphonates; Humans; Imidazoles; Male; Multivariate Analysis; Peptide Fragments; Peptides; Predictive Value of Tests; Procollagen; Prostate-Specific Antigen; Prostatic Neoplasms; Regression Analysis; Zoledronic Acid	2009
Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma. Cancer, 2009, Aug-01, Volume: 115, Issue:15 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Pilot Projects; Prostatic Neoplasms; Zoledronic Acid	2009
Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. Trials, 2009, Jun-11, Volume: 10 Topics: Androgen Antagonists; Antineoplastic Agents; Data Interpretation, Statistical; Diphosphonates; Docetaxel; Drug Therapy, Combination; Humans; Imidazoles; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Software; Taxoids; Zoledronic Acid	2009
Phase I trial of zoledronic acid + imatinib mesylate (Gleevec) in patients with bone metastases. American journal of clinical oncology, 2010, Volume: 33, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imatinib Mesylate; Imidazoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Staging; Piperazines; Prognosis; Prostatic Neoplasms; Pyrimidines; Sarcoma; Survival Rate; Treatment Outcome; Zoledronic Acid	2010
Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy. The Journal of urology, 2009, Volume: 182, Issue:5 Topics: Aged; Androgen Antagonists; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Male; Osteoporosis; Prostatic Neoplasms; Risk Factors; Veterans; Zoledronic Acid	2009
Docetaxel-based chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: factors predicting response and survival. International journal of urology : official journal of the Japanese Urological Association, 2009, Volume: 16, Issue:9 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Diphosphonates; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Imidazoles; Karnofsky Performance Status; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prednisone; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome; Zoledronic Acid	2009
Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer. BJU international, 2010, Volume: 105, Issue:8 Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Bone Density Conservation Agents; Diphosphonates; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Male; Middle Aged; Nitriles; Osteoporosis; Prospective Studies; Prostatic Neoplasms; Tosyl Compounds; Zoledronic Acid	2010
Long term zoledronic acid during androgen blockade for prostate cancer. The Canadian journal of urology, 2010, Volume: 17, Issue:3 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Diphosphonates; Goserelin; Humans; Imidazoles; Male; Middle Aged; Prostatic Neoplasms; Time Factors; Zoledronic Acid	2010
Titration of dosage for the protective effect of zoledronic acid on bone loss in patients submitted to androgen deprivation therapy due to prostate cancer: a prospective open-label study. Urologia internationalis, 2010, Volume: 85, Issue:2 Topics: Absorptiometry, Photon; Adenocarcinoma; Aged; Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Brazil; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Infusions, Intravenous; Lumbar Vertebrae; Male; Neoplasm Recurrence, Local; Osteoporosis; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Time Factors; Treatment Outcome; Zoledronic Acid	2010
Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial. Cancer biology & therapy, 2010, Sep-15, Volume: 10, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Diphosphonates; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Fever; Humans; Imidazoles; Infusions, Intravenous; Interleukin-8; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Neutropenia; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome; Zoledronic Acid	2010
Risk of skeletal-related events in patients with advanced prostate cancer treated with pamidronate or zoledronic acid. The Annals of pharmacotherapy, 2010, Volume: 44, Issue:9 Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Humans; Imidazoles; Male; Pamidronate; Prostatic Neoplasms; Retrospective Studies; Risk; Treatment Outcome; Zoledronic Acid	2010
Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer. Urology, 2010, Volume: 76, Issue:5 Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Pain; Pain Measurement; Prostatic Neoplasms; Spinal Cord Compression; Survival Rate; Zoledronic Acid	2010
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet (London, England), 2011, Mar-05, Volume: 377, Issue:9768 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid	2011
Cost effectiveness of zoledronic acid in the management of skeletal metastases in hormone-refractory prostate cancer patients in France, Germany, Portugal, and the Netherlands. Journal of medical economics, 2011, Volume: 14, Issue:3 Topics: Aged; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Cost-Benefit Analysis; Diphosphonates; Europe; Health Care Costs; Hormones; Humans; Imidazoles; Male; Prostatic Neoplasms; Quality of Life; Surveys and Questionnaires; Zoledronic Acid	2011
Zoledronic acid to prevent bone loss in Chinese men receiving androgen deprivation therapy for prostate cancer. Asia-Pacific journal of clinical oncology, 2011, Volume: 7, Issue:2 Topics: Aged; Androgen Antagonists; Asian People; Bone Density; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Male; Orchiectomy; Osteoporosis; Prostatic Neoplasms; Zoledronic Acid	2011
Bisphosphonate-related osteonecrosis: laser-assisted surgical treatment or conventional surgery? Lasers in medical science, 2011, Volume: 26, Issue:6 Topics: Adult; Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Breast Neoplasms; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Lasers, Solid-State; Low-Level Light Therapy; Lung Neoplasms; Male; Middle Aged; Peptides; Prostatic Neoplasms; Retrospective Studies; Zoledronic Acid	2011
Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. Journal of managed care pharmacy : JMCP, 2011, Volume: 17, Issue:8 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Cohort Studies; Cost-Benefit Analysis; Denosumab; Diphosphonates; Disease Progression; Drug Costs; Health Care Costs; Humans; Imidazoles; Male; Markov Chains; Models, Economic; Multivariate Analysis; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Sensitivity and Specificity; United States; Zoledronic Acid	2011
Possible anti-tumor activity of initial treatment with zoledronic acid with hormonal therapy for bone-metastatic prostate cancer in multicenter clinical trial. International journal of clinical oncology, 2013, Volume: 18, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Disease-Free Survival; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid	2013
Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration. The oncologist, 2012, Volume: 17, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Disease Progression; Double-Blind Method; Humans; Hyperparathyroidism, Secondary; Imidazoles; Male; Middle Aged; Multivariate Analysis; Parathyroid Hormone; Prognosis; Prostatic Neoplasms; Survival Analysis; Zoledronic Acid	2012
High-dose calcitriol, docetaxel and zoledronic acid in patients with castration-resistant prostate cancer: a phase II study. Urologia internationalis, 2013, Volume: 90, Issue:1 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Diphosphonates; Docetaxel; Drug Administration Schedule; Humans; Imidazoles; Infusions, Intravenous; Kallikreins; Kaplan-Meier Estimate; Lebanon; Male; Middle Aged; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Time Factors; Treatment Outcome; Zoledronic Acid	2013
Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial. The Lancet. Oncology, 2012, Volume: 13, Issue:12 Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Brachytherapy; Diphosphonates; Humans; Imidazoles; Leuprolide; Male; Middle Aged; Neoadjuvant Therapy; Prostatic Neoplasms; Quality of Life; Radiotherapy Dosage; Zoledronic Acid	2012
[Efficacy of 153Sm-EDTMP in the treatment of prostate cancer with bone metastasis]. Zhonghua nan ke xue = National journal of andrology, 2012, Volume: 18, Issue:11 Topics: Aged; Aged, 80 and over; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Organometallic Compounds; Organophosphorus Compounds; Prostatic Neoplasms; Zoledronic Acid	2012
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Journal of the National Cancer Institute, 2002, Oct-02, Volume: 94, Issue:19 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Biomarkers; Bone Density; Bone Neoplasms; Bone Resorption; Diphosphonates; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Imidazoles; Infusions, Intravenous; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Quality of Life; Treatment Outcome; Zoledronic Acid	2002
Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Journal of the National Cancer Institute, 2003, Feb-19, Volume: 95, Issue:4 Topics: Androgens; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Pain; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid	2003
Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Journal of the National Cancer Institute, 2003, Feb-19, Volume: 95, Issue:4 Topics: Alkaline Phosphatase; Androgens; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Parathyroid Hormone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Zoledronic Acid	2003
Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Journal of the National Cancer Institute, 2003, Feb-19, Volume: 95, Issue:4 Topics: Androgens; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Pain; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid	2003
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. The Journal of urology, 2003, Volume: 169, Issue:6 Topics: Aged; Androgen Antagonists; Bone Density; Diphosphonates; Double-Blind Method; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Male; Orchiectomy; Osteoporosis; Prostatic Neoplasms; Zoledronic Acid	2003
Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:7 Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Kidney; Male; Multiple Myeloma; Neoplasm Metastasis; Placebos; Prostatic Neoplasms; Time Factors; United States; United States Food and Drug Administration; Zoledronic Acid	2003
A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). Journal of the National Cancer Institute, 2003, Sep-03, Volume: 95, Issue:17 Topics: Administration, Oral; Aged; Analgesics, Non-Narcotic; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Neoplasms; Clodronic Acid; Digestive System; Diphosphonates; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Humans; Imidazoles; Male; Middle Aged; Odds Ratio; Pain; Prostatic Neoplasms; Research Design; Survival Analysis; Treatment Outcome; United Kingdom; Zoledronic Acid	2003
Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. The Journal of urology, 2004, Volume: 171, Issue:4 Topics: Aged; Bone Neoplasms; Cost-Benefit Analysis; Diphosphonates; Double-Blind Method; Follow-Up Studies; Humans; Imidazoles; Male; Prospective Studies; Prostatic Neoplasms; Zoledronic Acid	2004
Zoledronic acid is effective in the treatment of prostate cancer patients with bone metastases. Clinical prostate cancer, 2002, Volume: 1, Issue:1 Topics: Aged; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Treatment Outcome; Zoledronic Acid	2002
Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer. Urology, 2004, Volume: 63, Issue:5 Topics: Aged; Antineoplastic Agents; Benzamides; Bone Diseases; Bone Neoplasms; Bone Resorption; Diphosphonates; Disease Progression; Drug Therapy, Combination; Humans; Imatinib Mesylate; Imidazoles; Male; Middle Aged; Pain; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrimidines; Treatment Failure; Zoledronic Acid	2004
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. Journal of the National Cancer Institute, 2004, Jun-02, Volume: 96, Issue:11 Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Drug Administration Schedule; Humans; Imidazoles; Incidence; Male; Middle Aged; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid	2004
Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer. BJU international, 2004, Volume: 94, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Male; Middle Aged; Pilot Projects; Prostatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome; Zoledronic Acid	2004
Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. The oncologist, 2004, Volume: 9, Issue:6 Topics: Aged; Arthralgia; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Creatinine; Diphosphonates; Fatigue; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Nausea; Pain; Pain Measurement; Prospective Studies; Prostatic Neoplasms; Quality of Life; Treatment Outcome; Zoledronic Acid	2004
[Use of zoledronic acid for high risk prostate cancer patients]. Der Urologe. Ausg. A, 2005, Volume: 44, Issue:2 Topics: Animals; Bone Neoplasms; Diphosphonates; Drug Administration Schedule; Europe; Humans; Hypercalcemia; Imidazoles; Injections, Intravenous; Male; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid	2005
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, May-01, Volume: 23, Issue:13 Topics: Aged; Androgen Antagonists; Biomarkers, Tumor; Bone Neoplasms; Diphosphonates; Disease Progression; Double-Blind Method; Follow-Up Studies; Humans; Imidazoles; Male; Placebos; Predictive Value of Tests; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Zoledronic Acid	2005
Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer. Clinical prostate cancer, 2005, Volume: 4, Issue:1 Topics: Aged; Bone Neoplasms; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Incidence; Male; Pain; Prostatic Neoplasms; Quality of Life; Retrospective Studies; Spinal Cord Compression; Zoledronic Acid	2005
Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients. Cancer chemotherapy and pharmacology, 2006, Volume: 57, Issue:1 Topics: Aged; Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Imidazoles; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Zoledronic Acid	2006
In focus: prostate cancer. Clinical advances in hematology & oncology : H&O, 2003, Volume: 1, Issue:5 Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Protocols; Diphosphonates; Humans; Imidazoles; Male; Patient Selection; Prostatic Neoplasms; Zoledronic Acid	2003
Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. Urology, 2005, Volume: 66, Issue:5 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms; Zoledronic Acid	2005
The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers. Journal of chemotherapy (Florence, Italy), 2005, Volume: 17, Issue:5 Topics: Aged; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Pain; Pain Measurement; Prostatic Neoplasms; Zoledronic Acid	2005
Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:6 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Male; Pain; Pain Measurement; Placebos; Prostatic Neoplasms; Zoledronic Acid	2006
Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jun-01, Volume: 12, Issue:11 Pt 1 Topics: Aged; Alkaline Phosphatase; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Diphosphonates; Disease Progression; Follow-Up Studies; Humans; Imidazoles; Male; Multicenter Studies as Topic; Multivariate Analysis; Peptides; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome; Zoledronic Acid	2006
Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer, 2006, Aug-01, Volume: 107, Issue:3 Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Biomarkers, Tumor; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Disease Progression; Dyspnea; Edema; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Pyrrolidines; Treatment Outcome; Zoledronic Acid	2006
Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. The Journal of urology, 2006, Volume: 176, Issue:3 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Time Factors; Zoledronic Acid	2006
CALGB 90202. Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:12 Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid	2006
Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer. Urology, 2007, Volume: 69, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Follow-Up Studies; Gemcitabine; Humans; Imidazoles; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Hormone-Dependent; Pain Measurement; Palliative Care; Prednisone; Probability; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment; Survival Rate; Treatment Outcome; Zoledronic Acid	2007
Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression. European urology, 2007, Volume: 52, Issue:5 Topics: Aged; Alkaline Phosphatase; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Collagen Type I; Diphosphonates; Disease Progression; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Peptide Fragments; Peptides; Procollagen; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid	2007
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. European urology, 2007, Volume: 52, Issue:4 Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; Bone Neoplasms; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Survivors; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Zoledronic Acid	2007
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Mar-20, Volume: 25, Issue:9 Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Boston; Diphosphonates; Drug Administration Schedule; Fractures, Bone; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Osteoporosis; Prostatic Neoplasms; Time Factors; Treatment Outcome; Zoledronic Acid	2007
Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study. International journal of urology : official journal of the Japanese Urological Association, 2007, Volume: 14, Issue:4 Topics: Adenocarcinoma; Aged; Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Clodronic Acid; Diphosphonates; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Orchiectomy; Osteoporosis; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Zoledronic Acid	2007
Zoledronic acid treatment at home: safety data from an observational prospective trial. Journal of palliative medicine, 2007, Volume: 10, Issue:2 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Creatinine; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Feasibility Studies; Female; Home Care Services; Humans; Imidazoles; Karnofsky Performance Status; Male; Middle Aged; Multiple Myeloma; Observation; Prospective Studies; Prostatic Neoplasms; Survival Analysis; Time Factors; Zoledronic Acid	2007
Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. BJU international, 2007, Volume: 100, Issue:1 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Diphosphonates; Double-Blind Method; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Male; Middle Aged; Orchiectomy; Osteoporosis; Prostatic Neoplasms; Retrospective Studies; Treatment Outcome; Zoledronic Acid	2007
The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clinical genitourinary cancer, 2007, Volume: 5, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Placebos; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid	2007
Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy. Urology, 2007, Volume: 70, Issue:1 Topics: Aged; Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Cross-Sectional Studies; Diphosphonates; Humans; Imidazoles; Life Style; Male; Prostatic Neoplasms; Time Factors; Zoledronic Acid	2007
Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology, 2007, Volume: 70, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Castration; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Prostatic Neoplasms; Treatment Failure; Zoledronic Acid	2007
Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC). Investigational new drugs, 2008, Volume: 26, Issue:1 Topics: Administration, Oral; Aged; Aged, 80 and over; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Estramustine; Fatigue; Humans; Hypocalcemia; Imidazoles; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Thrombocytopenia; Time Factors; Treatment Outcome; Zoledronic Acid	2008
Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Clinical genitourinary cancer, 2007, Volume: 5, Issue:6 Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Pain; Prostatic Neoplasms; Retrospective Studies; Zoledronic Acid	2007
A prospective, multicenter, open-label trial of zoledronic acid in patients with hormone refractory prostate cancer. Yonsei medical journal, 2007, Dec-31, Volume: 48, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Bone Neoplasms; Creatinine; Diphosphonates; Drug Resistance, Neoplasm; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms; Quality of Life; Treatment Outcome; Zoledronic Acid	2007

Other Studies

219 other study(ies) available for zoledronic acid and Prostatic Neoplasms

Article	Year
Initiation of bone-targeted agents in patients with bone metastases and breast or castrate-resistant prostate cancer actively treated in routine clinical practice in Europe. Bone, 2022, Volume: 154 Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Germany; Humans; Male; Prostatic Neoplasms; Zoledronic Acid	2022
Discontinuation of denosumab in men with prostate cancer. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2023, Volume: 34, Issue:2 Topics: Androgen Antagonists; Androgens; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Denosumab; Humans; Male; Prostatic Neoplasms; Retrospective Studies; Zoledronic Acid	2023
Efficacy of zoledronic acid for the elimination of disseminated tumor cells in a clinically relevant, spontaneously metastatic prostate cancer xenograft model. Bone, 2023, Volume: 171 Topics: Androgen Antagonists; Animals; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Heterografts; Humans; Imidazoles; Male; Mice; Mice, SCID; Prostatic Neoplasms; Tumor Microenvironment; Zoledronic Acid	2023
Zoledronic acid and thymosin α1 elicit antitumor immunity against prostate cancer by enhancing tumor inflammation and cytotoxic T cells. Journal for immunotherapy of cancer, 2023, Volume: 11, Issue:6 Topics: Androgen Antagonists; Androgens; Animals; CD8-Positive T-Lymphocytes; Humans; Inflammation; Male; Mice; Prostatic Neoplasms; Retrospective Studies; T-Lymphocytes, Cytotoxic; Thymalfasin; Tumor Microenvironment; Zoledronic Acid	2023
[Risk Factors of Antiresorptive Agent-Related Osteonecrosis of the Jaw in Prostate Cancer Patients with Bone Metastases]. Hinyokika kiyo. Acta urologica Japonica, 2023, Volume: 69, Issue:5 Topics: Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Humans; Male; Osteonecrosis; Prostatic Neoplasms; Risk Factors; Zoledronic Acid	2023
Risk Factors for Bisphosphonate-Related Osteonecrosis of the Jaws in Bone Metastatic Breast and Prostate Cancer under Zoledronate Treatment: A Retrospective Analysis from 10 Years of Evaluation. Asian Pacific journal of cancer prevention : APJCP, 2023, Aug-01, Volume: 24, Issue:8 Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Breast; Humans; Male; Middle Aged; Prostatic Neoplasms; Retrospective Studies; Zoledronic Acid	2023
Guideline adherence in bone-targeted treatment of cancer patients with bone metastases in Germany. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2020, Volume: 28, Issue:5 Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Calcium, Dietary; Denosumab; Dietary Supplements; Female; Germany; Guideline Adherence; Humans; Lung Neoplasms; Male; Oncologists; Practice Patterns, Physicians'; Prostatic Neoplasms; Retrospective Studies; Surveys and Questionnaires; Vitamin D; Vitamins; Zoledronic Acid	2020
Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy. Clinical advances in hematology & oncology : H&O, 2019, Volume: 17, Issue:7 Topics: Abiraterone Acetate; Absorptiometry, Photon; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisolone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid	2019
Association of Behavioral Nudges With High-Value Evidence-Based Prescribing in Oncology. JAMA oncology, 2020, 07-01, Volume: 6, Issue:7 Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Choice Behavior; Denosumab; Female; Humans; Lung Neoplasms; Male; Medical Oncology; Middle Aged; Oncologists; Practice Patterns, Physicians'; Prostatic Neoplasms; Zoledronic Acid	2020
Medication-Related Osteonecrosis of the Jaw. The American journal of the medical sciences, 2020, Volume: 360, Issue:3 Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Humans; Male; Maxilla; Necrosis; Prostatic Neoplasms; Tomography, X-Ray Computed; Zoledronic Acid	2020
Re: Is There a Benefit of Additional Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years with Hormone-Sensitive Advanced Prostate Cancer? A Meta-Analysis. The Journal of urology, 2020, Volume: 204, Issue:5 Topics: Androstenes; Celecoxib; Docetaxel; Humans; Male; Prostatic Neoplasms; Zoledronic Acid	2020
Antiresorptive agent-related osteonecrosis of the jaw in prostate cancer patients with bone metastasis treated with bone-modifying agents. Journal of bone and mineral metabolism, 2021, Volume: 39, Issue:2 Topics: Aged; Aged, 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Disease-Free Survival; Humans; Male; Middle Aged; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Zoledronic Acid	2021
Cytotoxic and anti-angiogenic effects of zoledronic acid in DU-145 and PC-3 prostate cancer cell lines. Molecular biology reports, 2020, Volume: 47, Issue:10 Topics: Angiogenesis Inhibitors; Apoptosis; Cytotoxins; Humans; Male; PC-3 Cells; Prostatic Neoplasms; Zoledronic Acid	2020
Bone-Targeted Calcium Phosphate-Polymer Hybrid Nanoparticle Co-Deliver Zoledronate and Docetaxel to Treat Bone Metastasis of Prostate Cancer. Journal of pharmaceutical sciences, 2021, Volume: 110, Issue:2 Topics: Antineoplastic Agents; Calcium Phosphates; Cell Line, Tumor; Docetaxel; Humans; Male; Nanoparticles; Polymers; Prostatic Neoplasms; Zoledronic Acid	2021
Effects of once-yearly zoledronic acid on bone density and incident vertebral fractures in nonmetastatic castration-sensitive prostate cancer patients with osteoporosis. BMC cancer, 2021, Apr-17, Volume: 21, Issue:1 Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Comorbidity; Drug Administration Schedule; Humans; Japan; Kidney Function Tests; Male; Middle Aged; Osteoporosis; Prostatic Neoplasms; Public Health Surveillance; Retrospective Studies; Risk Factors; Spinal Fractures; Zoledronic Acid	2021
Self-assembling nanoparticles encapsulating zoledronic acid inhibit mesenchymal stromal cells differentiation, migration and secretion of proangiogenic factors and their interactions with prostate cancer cells. Oncotarget, 2017, Jun-27, Volume: 8, Issue:26 Topics: Adipocytes; Angiogenesis Inducing Agents; Cell Communication; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Survival; Cytokines; Diphosphonates; Humans; Imidazoles; Male; Mesenchymal Stem Cells; Nanoparticles; Osteoblasts; Osteoclasts; Prostatic Neoplasms; Tumor Microenvironment; Zoledronic Acid	2017
Prostate cancer: A new standard-of-care for advanced-stage disease. Nature reviews. Clinical oncology, 2017, Volume: 14, Issue:10 Topics: Docetaxel; Humans; Male; Prostatectomy; Prostatic Neoplasms; Zoledronic Acid	2017
A Subpopulation of Stromal Cells Controls Cancer Cell Homing to the Bone Marrow. Cancer research, 2018, 01-01, Volume: 78, Issue:1 Topics: Animals; Bone Marrow; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Female; Humans; Imidazoles; Male; Mesenchymal Stem Cells; Mice, Mutant Strains; Parathyroid Hormone; Prenylation; Prostatic Neoplasms; Stem Cell Niche; Xenograft Model Antitumor Assays; Zoledronic Acid	2018
Treatment dynamics of bone-targeting agents among men with bone metastases from prostate cancer in the United States. Pharmacoepidemiology and drug safety, 2018, Volume: 27, Issue:2 Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Drug Utilization; Humans; Longitudinal Studies; Male; Middle Aged; Practice Patterns, Physicians'; Prostatic Neoplasms; Time Factors; United States; Zoledronic Acid	2018
Effect of zoledronic acid dosing every 3 months in patients with prostate cancer with skeletal metastases: A multicenter prospective exploratory study with matched historical controls. International journal of urology : official journal of the Japanese Urological Association, 2018, Volume: 25, Issue:8 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Fractures, Spontaneous; Humans; Male; Middle Aged; Multivariate Analysis; Propensity Score; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Zoledronic Acid	2018
Microbial diversity in infections of patients with medication-related osteonecrosis of the jaw. Clinical oral investigations, 2019, Volume: 23, Issue:5 Topics: Actinomyces; Aged; Aged, 80 and over; Bacterial Infections; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Male; Middle Aged; Prevotella; Prostatic Neoplasms; Streptococcus; Veillonella; Zoledronic Acid	2019
Androgen deprivation therapy in prostate cancer: new findings and questions for the future. The Lancet. Oncology, 2019, Volume: 20, Issue:2 Topics: Androgen Antagonists; Humans; Male; Prostatic Neoplasms; Zoledronic Acid	2019
Zoledronic Acid Inhibits the RhoA-mediated Amoeboid Motility of Prostate Cancer Cells. Current cancer drug targets, 2019, Volume: 19, Issue:10 Topics: Animals; Bone Density Conservation Agents; Cell Movement; Humans; Male; Mice; Mice, SCID; Osteoclasts; PC-3 Cells; Prostatic Neoplasms; rhoA GTP-Binding Protein; Xenograft Model Antitumor Assays; Zoledronic Acid	2019
Uncommon presentation of medication-related osteonecrosis of the mandible in a patient with metastatic prostate cancer. BMJ case reports, 2019, Feb-26, Volume: 12, Issue:2 Topics: Aged, 80 and over; Anti-Bacterial Agents; Bone Density Conservation Agents; Free Radical Scavengers; Humans; Male; Mandible; Osteonecrosis; Pentoxifylline; Prostatic Neoplasms; Vitamin E; Zoledronic Acid	2019
Skeletal-related events in metastatic prostate cancer and the number needed to treat: a critical consideration. Urologia internationalis, 2013, Volume: 90, Issue:3 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Bone Diseases; Denosumab; Diphosphonates; Drug Administration Schedule; Humans; Imidazoles; Life Expectancy; Male; Numbers Needed To Treat; Osteoporosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Spinal Fractures; Time Factors; Treatment Outcome; Zoledronic Acid	2013
Zoledronic acid administration in aggressive castration- resistant prostate cancer. Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:12 Topics: Aged; Bone and Bones; Bone Diseases; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid	2012
[Home-based zoledronic acid infusion therapy in patients with solid tumours: compliance and patient-nurse satisfaction]. Bulletin du cancer, 2013, Volume: 100, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Benchmarking; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Feasibility Studies; Female; Home Infusion Therapy; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Nurse-Patient Relations; Nursing Staff; Patient Compliance; Patient Satisfaction; Personal Satisfaction; Prospective Studies; Prostatic Neoplasms; Surveys and Questionnaires; Zoledronic Acid	2013
Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells. Cell death & disease, 2013, May-23, Volume: 4 Topics: Antineoplastic Agents; Cell Movement; Diphosphonates; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Exotoxins; Humans; Imidazoles; Interleukin-12; Male; p38 Mitogen-Activated Protein Kinases; Phenotype; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyridines; Vascular Endothelial Growth Factor A; Zoledronic Acid	2013
Effects of bisphosphonates in combination with ionizing radiation and antioxidants on the growth of prostate and melanoma cells lines. Anticancer research, 2013, Volume: 33, Issue:8 Topics: Animals; Antioxidants; Apigenin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; Melanoma; Mice; Pamidronate; Prostatic Neoplasms; Radiation, Ionizing; Skin Neoplasms; Zoledronic Acid	2013
Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic. The Bulletin of Tokyo Dental College, 2013, Volume: 54, Issue:2 Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Arthritis, Rheumatoid; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diabetes Complications; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Imidazoles; Infusions, Parenteral; Japan; Male; Middle Aged; Oral Surgical Procedures; Osteoporosis; Prostatic Neoplasms; Risedronic Acid; Treatment Outcome; Wound Healing; Zoledronic Acid	2013
Balancing toxicity and efficacy: learning from trials and treatment using antiresorptive therapy in prostate cancer. European urology, 2014, Volume: 65, Issue:2 Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Male; Osteoclasts; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid	2014
[Case of prostate cancer associated with bisphosphonate-related osteonecrosis of the jaw followed by retropharyngeal abscess]. Hinyokika kiyo. Acta urologica Japonica, 2013, Volume: 59, Issue:9 Topics: Aged; Anti-Bacterial Agents; Antineoplastic Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Docetaxel; Drainage; Fatal Outcome; Humans; Imidazoles; Jaw; Male; Prostatic Neoplasms; Retropharyngeal Abscess; Taxoids; Tomography, X-Ray Computed; Zoledronic Acid	2013
Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways. Cell death & disease, 2013, Oct-24, Volume: 4 Topics: Animals; Antineoplastic Agents; Apoptosis; Diphosphonates; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Humans; Hydroxamic Acids; Imidazoles; Indoles; Male; Mevalonic Acid; Mice; Mice, Nude; Models, Biological; Multiple Myeloma; p38 Mitogen-Activated Protein Kinases; Panobinostat; Prostatic Neoplasms; Reactive Oxygen Species; Signal Transduction; Xenograft Model Antitumor Assays; Zoledronic Acid	2013
US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Feb-01, Volume: 32, Issue:4 Topics: Androstenes; Androstenols; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Denosumab; Diphosphonates; Docetaxel; Drug Approval; Drugs, Investigational; Estramustine; Goserelin; Humans; Imidazoles; Male; Mitoxantrone; Nitriles; Oligopeptides; Phenylthiohydantoin; Prostatic Neoplasms; Radioisotopes; Radium; Taxoids; Tissue Extracts; United States; United States Food and Drug Administration; Zoledronic Acid	2014
Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2014, Volume: 22, Issue:5 Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Pamidronate; Prostatic Neoplasms; Zoledronic Acid	2014
Does regular zoledronic acid change the bone turnover of the jaw in men with metastatic prostate cancer: a possible clue to the pathogenesis of bisphosphonate related osteonecrosis of the jaw? Journal of cancer research and clinical oncology, 2014, Volume: 140, Issue:3 Topics: Aged; Aged, 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Diphosphonates; Female; Femur; Frontal Bone; Germany; Humans; Imidazoles; Male; Mandible; Maxilla; Middle Aged; Prostatic Neoplasms; Radionuclide Imaging; Retrospective Studies; Sex Factors; Zoledronic Acid	2014
Prostate cancer: preventing metastasis to bone: is this the end of the story? Nature reviews. Urology, 2014, Volume: 11, Issue:5 Topics: Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Neoplasm Metastasis; Prostatic Neoplasms; Treatment Failure; Zoledronic Acid	2014
Time and labor costs associated with administration of intravenous bisphosphonates for breast or prostate cancer patients with metastatic bone disease: a time and motion study. Hospital practice (1995), 2014, Volume: 42, Issue:2 Topics: Aged; Ambulatory Care; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Canada; Costs and Cost Analysis; Cross-Sectional Studies; Diphosphonates; Equipment and Supplies; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Pamidronate; Prospective Studies; Prostatic Neoplasms; Time Factors; Zoledronic Acid	2014
New uses for rehabilitation protocol for oral sinus communications in ARONJ patients. Journal of prosthodontics : official journal of the American College of Prosthodontists, 2014, Volume: 23, Issue:8 Topics: Adenocarcinoma; Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Clinical Protocols; Dental Prosthesis Design; Denture Design; Denture, Complete, Upper; Diphosphonates; Follow-Up Studies; Humans; Imidazoles; Jaw, Edentulous; Male; Maxilla; Neoadjuvant Therapy; Oroantral Fistula; Palatal Obturators; Patient Care Planning; Prostatic Neoplasms; Zoledronic Acid	2014
Fluorescence-guided surgery of prostate cancer bone metastasis. The Journal of surgical research, 2014, Volume: 192, Issue:1 Topics: Adenocarcinoma; Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Disease-Free Survival; Green Fluorescent Proteins; Humans; Imidazoles; Luminescent Proteins; Lymphatic Metastasis; Male; Mice, Nude; Neoplasm Recurrence, Local; Neoplasm, Residual; Optical Imaging; Prostatic Neoplasms; Red Fluorescent Protein; Zoledronic Acid	2014
Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. Endocrine-related cancer, 2014, Volume: 21, Issue:5 Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Castration; Cell Line, Tumor; Diphosphonates; Humans; Imidazoles; Male; Mice, Inbred BALB C; Prostatic Neoplasms; Tumor Burden; Zoledronic Acid	2014
Auto-fluorescence of the bone and its use for delineation of bone necrosis. International journal of oral and maxillofacial surgery, 2014, Volume: 43, Issue:11 Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Male; Optical Imaging; Prostatic Neoplasms; Zoledronic Acid	2014
Role of bisphosphonates in non-metastatic prostate cancer. The Lancet. Oncology, 2014, Volume: 15, Issue:10 Topics: Adenocarcinoma; Androgen Antagonists; Brachytherapy; Diphosphonates; Humans; Imidazoles; Male; Neoplasm Recurrence, Local; Prostatic Neoplasms; Zoledronic Acid	2014
Zoledronic acid at the time of castration prevented castration-induced bone metastasis in mice. Endocrine-related cancer, 2014, Volume: 21, Issue:5 Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Castration; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid	2014
Hypernociceptive responses following the intratibial inoculation of RM1 prostate cancer cells in mice. The Prostate, 2015, Volume: 75, Issue:1 Topics: Animals; Bone Neoplasms; Calcium-Binding Proteins; Cell Line, Tumor; Chemokines; Diphosphonates; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Glial Fibrillary Acidic Protein; Hyperalgesia; Imidazoles; Immunohistochemistry; Male; Mice, Inbred C57BL; Microfilament Proteins; Morphine; Neoplasm Transplantation; Nerve Tissue Proteins; Nociceptive Pain; Prostatic Neoplasms; Receptors, CCR2; Spinal Cord; Tibia; Zoledronic Acid	2015
Zoledronic acid increases cytotoxicity by inducing apoptosis in hormone and docetaxel-resistant prostate cancer cell lines. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015, Volume: 36, Issue:2 Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Taxoids; Zoledronic Acid	2015
Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients. Journal of cancer research and clinical oncology, 2015, Volume: 141, Issue:4 Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Germany; Hematologic Neoplasms; Humans; Ibandronic Acid; Imidazoles; Jaw Diseases; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multiple Myeloma; Neoplasms; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Registries; Risk Factors; Sex Factors; Time Factors; Zoledronic Acid	2015
Upregulation of the mevalonate pathway by cholesterol depletion abolishes tolerance to N-bisphosphonate induced Vγ9Vδ2 T cell cytotoxicity in PC-3 prostate cancer cells. Cancer letters, 2015, Feb-01, Volume: 357, Issue:1 Topics: Cell Line, Tumor; Cholesterol; Cytotoxicity, Immunologic; Diphosphonates; Humans; Imidazoles; Male; Mevalonic Acid; Prostatic Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; Signal Transduction; T-Lymphocytes; Up-Regulation; Zoledronic Acid	2015
Safety of I.V. Nonnitrogen bisphosphonates on the occurrence of osteonecrosis of the jaw: long-term follow-up on prostate cancer patients. Clinical genitourinary cancer, 2015, Volume: 13, Issue:3 Topics: Administration, Intravenous; Aged; Androgen Antagonists; Bisphosphonate-Associated Osteonecrosis of the Jaw; Clodronic Acid; Diphosphonates; Drug Administration Schedule; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid	2015
Proteomic analysis of zoledronic-acid resistant prostate cancer cells unveils novel pathways characterizing an invasive phenotype. Oncotarget, 2015, Mar-10, Volume: 6, Issue:7 Topics: Blotting, Western; Bone Density Conservation Agents; Cell Movement; Cell Proliferation; Diphosphonates; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Gene Ontology; Gene Regulatory Networks; Humans; Imidazoles; Male; Neoplasm Invasiveness; Prostatic Neoplasms; Proteomics; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured; Zoledronic Acid	2015
Nanoparticles for the delivery of zoledronic acid to prostate cancer cells: a comparative analysis through time lapse video-microscopy technique. Cancer biology & therapy, 2014, Volume: 15, Issue:11 Topics: Antineoplastic Agents; Bone Density Conservation Agents; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; Diphosphonates; Dose-Response Relationship, Drug; Drug Compounding; Drug Delivery Systems; Humans; Imidazoles; Liposomes; Male; Nanoparticles; Prostatic Neoplasms; Time-Lapse Imaging; Zoledronic Acid	2014
Effects of zoledronic acid and docetaxel on small GTP-binding proteins in prostate cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015, Volume: 36, Issue:6 Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Diphosphonates; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Male; Prostatic Neoplasms; ras Proteins; rhoA GTP-Binding Protein; Taxoids; Zoledronic Acid	2015
Annexin A1 is involved in the acquisition and maintenance of a stem cell-like/aggressive phenotype in prostate cancer cells with acquired resistance to zoledronic acid. Oncotarget, 2015, Sep-22, Volume: 6, Issue:28 Topics: Annexin A1; Antineoplastic Agents; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Cell Differentiation; Cell Line, Tumor; Cell Shape; Diphosphonates; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Imidazoles; Male; Neoplastic Stem Cells; Phenotype; Prostatic Neoplasms; RNA Interference; Signal Transduction; Transfection; Zoledronic Acid	2015
Tumor-targeting Salmonella typhimurium A1-R inhibits human prostate cancer experimental bone metastasis in mouse models. Oncotarget, 2015, Oct-13, Volume: 6, Issue:31 Topics: Animals; Biological Therapy; Bone Density Conservation Agents; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Green Fluorescent Proteins; Humans; Imidazoles; Male; Mice; Mice, Nude; Prostatic Neoplasms; Salmonella Infections, Animal; Salmonella typhimurium; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zoledronic Acid	2015
Potentiating the Anticancer Properties of Bisphosphonates by Nanocomplexation with the Cationic Amphipathic Peptide, RALA. Molecular pharmaceutics, 2016, Apr-04, Volume: 13, Issue:4 Topics: Alendronate; Animals; Antineoplastic Agents; Bone Density Conservation Agents; Cell Line, Tumor; Cell Survival; Diphosphonates; Humans; Imidazoles; Male; Mice; Nanoparticles; Peptides; Prostatic Neoplasms; Xenograft Model Antitumor Assays; Zoledronic Acid	2016
Inhibition of Survivin Is Associated with Zoledronic Acid-induced Apoptosis of Prostate Cancer Cells. Anticancer research, 2016, Volume: 36, Issue:3 Topics: Apoptosis; Cell Proliferation; Cell Survival; Diphosphonates; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Male; MicroRNAs; Prostatic Neoplasms; Survivin; Zoledronic Acid	2016
Defining new standards of care for men with prostate cancer. Lancet (London, England), 2016, Mar-19, Volume: 387, Issue:10024 Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Prostatic Neoplasms; Taxoids; Zoledronic Acid	2016
Zoledronic acid impairs stromal reactivity by inhibiting M2-macrophages polarization and prostate cancer-associated fibroblasts. Oncotarget, 2017, Jan-03, Volume: 8, Issue:1 Topics: Cancer-Associated Fibroblasts; Cell Line, Tumor; Cell Movement; Diphosphonates; Humans; Imidazoles; Macrophage Activation; Macrophages; Male; Mevalonic Acid; Neoplasm Metastasis; Neovascularization, Pathologic; Phenotype; Prostatic Neoplasms; rhoA GTP-Binding Protein; Stromal Cells; Tumor Microenvironment; Zoledronic Acid	2017
Re: Addition of Docetaxel, Zoledronic Acid, or Both to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial. European urology, 2016, Volume: 69, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Prostatic Neoplasms; Taxoids; Zoledronic Acid	2016
Re: Addition of Docetaxel, Zoledronic Acid, or Both to First-Line Long-Term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial. The Journal of urology, 2016, Volume: 196, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Diphosphonates; Disease-Free Survival; Docetaxel; Humans; Imidazoles; Male; Prostatic Neoplasms; Taxoids; Zoledronic Acid	2016
Zoledronic Acid in First-Line Treatment of Prostate Cancer. International journal of radiation oncology, biology, physics, 2017, 01-01, Volume: 97, Issue:1 Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid	2017
Addition of docetaxel and/or zoledronic acid to standard of care for hormone-naive prostate cancer: a cost-effectiveness analysis. Tumori, 2017, Jul-31, Volume: 103, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; China; Cost-Benefit Analysis; Diphosphonates; Disease Progression; Docetaxel; Humans; Imidazoles; Male; Markov Chains; Prostatic Neoplasms; Standard of Care; Taxoids; Zoledronic Acid	2017
Bone-Targeted Therapy in Prostate Cancer in 2017: Lost Opportunities, Confusion, and Controversy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, 05-10, Volume: 35, Issue:14 Topics: Celecoxib; Diphosphonates; Humans; Male; Prostatic Neoplasms; Zoledronic Acid	2017
Renal toxicity following zoledronic acid reversed with ibandronate in a prostate cancer patient with bone metastases. Urologia internationalis, 2008, Volume: 80, Issue:4 Topics: Acute Kidney Injury; Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Bone Neoplasms; Creatinine; Diphosphonates; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Male; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Retreatment; Risk Assessment; Treatment Outcome; Zoledronic Acid	2008
Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. European urology, 2008, Volume: 54, Issue:5 Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Cross-Sectional Studies; Diphosphonates; Follow-Up Studies; Germany; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Prevalence; Prognosis; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Zoledronic Acid	2008
[A case of hormone/docetaxel-refractory prostate cancer in which PSA level decreased after docetaxel+zoledronic acid treatment]. Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:7 Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Docetaxel; Drug Resistance, Neoplasm; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Male; Middle Aged; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Taxoids; Zoledronic Acid	2008
Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line. Journal of translational medicine, 2008, Aug-08, Volume: 6 Topics: Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Caspase 3; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Diphosphonates; Docetaxel; Drug Synergism; Enzyme Activation; Fluorescent Dyes; Humans; Imidazoles; In Situ Nick-End Labeling; Male; MAP Kinase Kinase 1; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Rhodamines; Taxoids; Time Factors; Zoledronic Acid	2008
Re: Christian Walter, Bilal Al-Nawas, Knut A. Grötz, et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 2008;54:1066-72. European urology, 2009, Volume: 55, Issue:4 Topics: Bone Density Conservation Agents; Diphosphonates; Disease Progression; Humans; Imidazoles; Jaw Diseases; Male; Osteonecrosis; Prevalence; Prostatic Neoplasms; Risk Factors; Zoledronic Acid	2009
Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer, 2008, Sep-15, Volume: 113, Issue:6 Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Databases, Factual; Diphosphonates; Female; Humans; Imidazoles; Insurance Claim Reporting; Lung Neoplasms; Male; Medical Records; Middle Aged; Prostatic Neoplasms; Retrospective Studies; United States; Zoledronic Acid	2008
STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trial. Clinical oncology (Royal College of Radiologists (Great Britain)), 2008, Volume: 20, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Neoplasm Metastasis; Pilot Projects; Prostatic Neoplasms; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Taxoids; Zoledronic Acid	2008
[Prescription of bisphosphonates in prostate cancer]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2008, Volume: 18, Issue:1 Suppl FM Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Disease Progression; Humans; Ibandronic Acid; Imidazoles; Injections; Male; Prognosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Zoledronic Acid	2008
Re: Christan Walter, Bilal Al-Nawas, Knut A. Grötz, et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 2008;54:1066-72. European urology, 2009, Volume: 55, Issue:3 Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Osteonecrosis; Prevalence; Prostatic Neoplasms; Risk Factors; Zoledronic Acid	2009
Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy, 2008, Volume: 10, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cells, Cultured; Colorectal Neoplasms; Cytokines; Cytotoxicity, Immunologic; Diphosphonates; Female; Humans; Imidazoles; Immunophenotyping; Immunotherapy, Adoptive; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; RNA; T-Lymphocytes; Zoledronic Acid	2008
Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells. Cell biology international, 2009, Volume: 33, Issue:2 Topics: Androgens; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 7; Cell Line, Tumor; Diphosphonates; DNA Fragmentation; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Male; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Zoledronic Acid	2009
Slow zoledronic acid releasing testis prostheses in the treatment of prostate cancer patients with bone metastases. Medical hypotheses, 2009, Volume: 73, Issue:3 Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Drug Implants; Humans; Imidazoles; Male; Models, Biological; Prostatic Neoplasms; Testis; Zoledronic Acid	2009
Indirect antitumor effects of bisphosphonates on prostatic LNCaP cells co-cultured with bone cells. Anticancer research, 2009, Volume: 29, Issue:4 Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Cell Proliferation; Coculture Techniques; Diphosphonates; Humans; Imidazoles; Luciferases; Male; Mice; Osteoblasts; Osteoclasts; Pamidronate; Prostatic Neoplasms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcriptional Activation; Tumor Cells, Cultured; Zoledronic Acid	2009
Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells. International journal of cancer, 2009, Nov-01, Volume: 125, Issue:9 Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cysteine-Rich Protein 61; Diphosphonates; Humans; Imidazoles; Male; Neoplasm Invasiveness; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Prostatic Neoplasms; Protein Prenylation; Signal Transduction; Zoledronic Acid	2009
Treatment of painful bone metastases in hormone-refractory prostate cancer with zoledronic acid and samarium-153-ethylenediaminetetramethylphosphonic acid combined. Journal of palliative medicine, 2009, Volume: 12, Issue:7 Topics: Aged; Analgesics, Non-Narcotic; Bone Density Conservation Agents; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Humans; Imidazoles; Male; Organometallic Compounds; Organophosphorus Compounds; Pain; Prostatic Neoplasms; Radiopharmaceuticals; Zoledronic Acid	2009
Orbital inflammation and optic neuropathy with zoledronic acid for metastatic prostate cancer. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 2009, Volume: 44, Issue:4 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combination; Fluorescein Angiography; Glucocorticoids; Humans; Ibuprofen; Imidazoles; Magnetic Resonance Imaging; Male; Optic Neuropathy, Ischemic; Orbital Pseudotumor; Prednisone; Prostatic Neoplasms; Zoledronic Acid	2009
Targeting apoptosis in the hormone- and drug-resistant prostate cancer cell line, DU-145, by gossypol/zoledronic acid combination. Cell biology international, 2009, Volume: 33, Issue:11 Topics: Apoptosis; Apoptosis Regulatory Proteins; Bone Density Conservation Agents; Cell Line, Tumor; Cell Proliferation; Contraceptive Agents, Male; Diphosphonates; DNA Fragmentation; Drug Resistance, Neoplasm; Drug Synergism; Gossypol; Hormones; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid	2009
Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy. Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Diphosphonates; Dose-Response Relationship, Drug; Doxorubicin; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid	2010
Editorial Comment to docetaxel-based combination chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival. International journal of urology : official journal of the Japanese Urological Association, 2009, Volume: 16, Issue:9 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Diphosphonates; Docetaxel; Drug Administration Schedule; Humans; Imidazoles; Male; Neoplasms, Hormone-Dependent; Prednisone; Prostatic Neoplasms; Taxoids; Treatment Outcome; Zoledronic Acid	2009
Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-10, Volume: 27, Issue:32 Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Greece; Humans; Ibandronic Acid; Imidazoles; Incidence; Jaw Diseases; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Risk Factors; Zoledronic Acid	2009
Management of metastatic bone pain with repeated doses of rhenium 186-HEDP in patients under therapy with zoledronic acid: a safe and additively effective practice. Cancer biotherapy & radiopharmaceuticals, 2009, Volume: 24, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Analgesics; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Etidronic Acid; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Organometallic Compounds; Pain; Pain Measurement; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid	2009
Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer. Cancer investigation, 2009, Volume: 27, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Imidazoles; Jaw Diseases; Lung Neoplasms; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Retrospective Studies; Spinal Cord Compression; Time Factors; Treatment Outcome; Zoledronic Acid	2009
Zoledronic acid decreases mRNA six-transmembrane epithelial antigen of prostate protein expression in prostate cancer cells. Journal of endocrinological investigation, 2010, Volume: 33, Issue:4 Topics: Antigens, Neoplasm; Apoptosis; Bone Density Conservation Agents; Caspase 3; Cell Line, Tumor; Diphosphonates; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Male; Oxidoreductases; Prostatic Neoplasms; RNA, Messenger; Zoledronic Acid	2010
A single pretreatment by zoledronic acid converts metastases from osteolytic to osteoblastic in the rat. Microscopy research and technique, 2010, Volume: 73, Issue:8 Topics: Animals; Bone Neoplasms; Diphosphonates; Femur; Imidazoles; Male; Osteoblasts; Osteoclasts; Osteolysis; Prostatic Neoplasms; Rats; X-Ray Microtomography; Zoledronic Acid	2010
Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:9 Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Castration; Collagen Type I; Diphosphonates; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Peptides; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Treatment Outcome; Zoledronic Acid	2010
The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis. Urology, 2010, Volume: 75, Issue:5 Topics: Aged; Androgen Antagonists; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Male; Orchiectomy; Osteoporosis; Prostatic Neoplasms; Severity of Illness Index; Zoledronic Acid	2010
Bisphosphonate-related osteonecrosis of the jaw combined with jaw metastasis of prostate adenocarcinoma: report of a case. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2010, Volume: 68, Issue:4 Topics: Adenocarcinoma; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Male; Mandibular Diseases; Mandibular Neoplasms; Middle Aged; Osteonecrosis; Prostatic Neoplasms; Zoledronic Acid	2010
Regulation of apoptosis-related molecules by synergistic combination of all-trans retinoic acid and zoledronic acid in hormone-refractory prostate cancer cell lines. Molecular biology reports, 2011, Volume: 38, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Caspase 3; Caspase 7; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphosphonates; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Neoplastic; Hormones; Humans; Imidazoles; Male; Prostatic Neoplasms; Receptors, Tumor Necrosis Factor; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Tretinoin; Zoledronic Acid	2011
Bone disease in prostate cancer. Asia-Pacific journal of clinical oncology, 2010, Volume: 6, Issue:1 Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid	2010
Risk factors contributing to the development of hypocalcemia after zoledronic acid administration in patients with bone metastases of solid tumor. Biological & pharmaceutical bulletin, 2010, Volume: 33, Issue:4 Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Calcium; Diphosphonates; Female; Humans; Hypocalcemia; Imidazoles; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Zoledronic Acid	2010
Editorial comment. Urology, 2010, Volume: 75, Issue:5 Topics: Androgen Antagonists; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Male; Orchiectomy; Osteoporosis; Prostatic Neoplasms; Severity of Illness Index; Zoledronic Acid	2010
Reversal of chemotherapy-induced leukopenia using granulocyte macrophage colony-stimulating factor promotes bone metastasis that can be blocked with osteoclast inhibitors. Cancer research, 2010, Jun-15, Volume: 70, Issue:12 Topics: Animals; Antineoplastic Agents, Alkylating; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Diphosphonates; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Imidazoles; Leukopenia; Male; Mice; Mice, Nude; Osteoclasts; Osteoprotegerin; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid	2010
Disease progression increases the risk of skeletal-related events in patients with bone metastases from castration-resistant prostate cancer, lung cancer, or other solid tumors. Cancer investigation, 2010, Volume: 28, Issue:8 Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Disease Progression; Female; Humans; Imidazoles; Lung Neoplasms; Male; Neoplasms; Orchiectomy; Placebos; Prostatic Neoplasms; Risk Factors; Zoledronic Acid	2010
[Study of sequence-dependent in vitro effects of zoledronic acid and paclitaxel upon DU145 prostate cancer cells]. Zhonghua yi xue za zhi, 2010, Apr-13, Volume: 90, Issue:14 Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Humans; Imidazoles; Male; Paclitaxel; Prostatic Neoplasms; Zoledronic Acid	2010
Zoledronate stimulates gamma delta T cells in prostate cancer patients. Oncology research, 2010, Volume: 18, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Immunotherapy; Interleukin-2; Lymphocyte Activation; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Zoledronic Acid	2010
[Expert consensus for the diagnosis and treatment of bone metastasis from prostate cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:5 Topics: Androgen Antagonists; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Prostatic Neoplasms; Taxoids; Zoledronic Acid	2010
Targeting the {alpha} receptor for platelet-derived growth factor as a primary or combination therapy in a preclinical model of prostate cancer skeletal metastasis. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Oct-15, Volume: 16, Issue:20 Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Humans; Imidazoles; Male; Mice; Mice, SCID; Molecular Targeted Therapy; NIH 3T3 Cells; Prostatic Neoplasms; Receptor, Platelet-Derived Growth Factor alpha; Xenograft Model Antitumor Assays; Zoledronic Acid	2010
Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases. The oncologist, 2010, Volume: 15, Issue:11 Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Jaw; Male; Osteonecrosis; Pamidronate; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid	2010
Self-assembly nanoparticles for the delivery of bisphosphonates into tumors. International journal of pharmaceutics, 2011, Jan-17, Volume: 403, Issue:1-2 Topics: Animals; Antineoplastic Agents; Calcium Phosphates; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Drug Compounding; Humans; Imidazoles; Liposomes; Male; Mice; Mice, Nude; Microscopy, Electron, Scanning; Nanoparticles; Particle Size; Polyethylene Glycols; Prostatic Neoplasms; Surface Properties; Tissue Distribution; Xenograft Model Antitumor Assays; Zoledronic Acid	2011
Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis. Current medical research and opinion, 2011, Volume: 27, Issue:1 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Cohort Studies; Diphosphonates; Follow-Up Studies; Humans; Imidazoles; Incidence; Male; Middle Aged; Prostatic Neoplasms; Retrospective Studies; Risk; Treatment Outcome; Zoledronic Acid	2011
Orbital inflammation after use of zoledronic acid for metastasized prostate carcinoma. Bulletin de la Societe belge d'ophtalmologie, 2010, Issue:315 Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Conjunctivitis, Acute Hemorrhagic; Diphosphonates; Humans; Imidazoles; Inflammation; Male; Neoplasms, Second Primary; Neurofibroma; Orbital Diseases; Orbital Neoplasms; Prostatic Neoplasms; Zoledronic Acid	2010
The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population. Prostate cancer and prostatic diseases, 2011, Volume: 14, Issue:1 Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Hospitalization; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Prostatic Neoplasms; Retrospective Studies; Risk Assessment; Time Factors; Treatment Outcome; United States; United States Department of Veterans Affairs; Zoledronic Acid	2011
Bone turnover markers as predictors of mortality risk in prostate cancer patients with bone metastases following treatment with zoledronic acid. European urology, 2011, Volume: 59, Issue:4 Topics: Aged; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Clinical Trials as Topic; Collagen Type I; Diphosphonates; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Multicenter Studies as Topic; Peptide Fragments; Peptides; Predictive Value of Tests; Procollagen; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Surveys and Questionnaires; Zoledronic Acid	2011
Zoledronic acid induces autophagic cell death in human prostate cancer cells. The Journal of urology, 2011, Volume: 185, Issue:4 Topics: Autophagy; Bone Density Conservation Agents; Cells, Cultured; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid	2011
Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates. Journal of cellular biochemistry, 2011, Volume: 112, Issue:6 Topics: Aged; Blotting, Western; Bone Density Conservation Agents; Cell Line, Tumor; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; In Vitro Techniques; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Prostatic Neoplasms; Proto-Oncogene Proteins; Reverse Transcriptase Polymerase Chain Reaction; Wnt Proteins; Wnt-5a Protein; Wnt1 Protein; Wnt4 Protein; Zoledronic Acid	2011
Unravelling the role of denosumab in prostate cancer. Lancet (London, England), 2011, Mar-05, Volume: 377, Issue:9768 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid	2011
[A case of castration-refractory prostate cancer showing marked decrease of serum PSA level after zoledronic acid treatment with estramustine phosphate and prednisolone]. Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Castration; Diphosphonates; Estramustine; Fatal Outcome; Humans; Imidazoles; Magnetic Resonance Imaging; Male; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid	2011
Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone. Bone, 2011, Jun-01, Volume: 48, Issue:6 Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Calcium; Cell Division; Cell Line, Tumor; Diphosphonates; Dogs; Imidazoles; Male; Mice; Mice, Nude; Osteoclasts; Prostatic Neoplasms; Zoledronic Acid	2011
Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. Nanomedicine : nanotechnology, biology, and medicine, 2011, Volume: 7, Issue:6 Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Drug Delivery Systems; Humans; Imidazoles; Liposomes; Male; Mice; Mice, Nude; Multiple Myeloma; Neovascularization, Pathologic; Prostate; Prostatic Neoplasms; Zoledronic Acid	2011
[Disseminated carcinomatosis of the bone marrow in two patients with prostate cancer]. Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2011, Volume: 102, Issue:1 Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Bone Marrow Neoplasms; Carcinoma; Diphosphonates; Disseminated Intravascular Coagulation; Drug Therapy, Combination; Fatal Outcome; Humans; Imidazoles; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome; Zoledronic Acid	2011
Is ¹⁵³Samarium-ethylene-diamine-tetramethyl-phosphonate (EDTMP) bone uptake influenced by bisphosphonates in patients with castration-resistant prostate cancer? World journal of urology, 2012, Volume: 30, Issue:2 Topics: Aged; Analgesics, Non-Narcotic; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Drug Interactions; Humans; Imidazoles; Male; Middle Aged; Musculoskeletal Pain; Orchiectomy; Organometallic Compounds; Organophosphorus Compounds; Prostatic Neoplasms; Radiopharmaceuticals; Retrospective Studies; Zoledronic Acid	2012
Prostate cancer: targeted therapy for prostate cancer metastases to bone. Nature reviews. Urology, 2011, May-17, Volume: 8, Issue:6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Clinical Trials, Phase III as Topic; Denosumab; Diphosphonates; Drug Delivery Systems; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid	2011
Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in patients with prostate cancer with bone metastasis. BJU international, 2012, Volume: 109, Issue:3 Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Collagen Type I; Diphosphonates; Drug Administration Schedule; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Peptide Fragments; Peptides; Procollagen; Prostatic Neoplasms; Retrospective Studies; Zoledronic Acid	2012
Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model. PloS one, 2011, Volume: 6, Issue:5 Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Imidazoles; Incidence; Male; Mice; Neoplasm Metastasis; Prostatic Neoplasms; Survival Rate; Zoledronic Acid	2011
Awareness and education of patients receiving bisphosphonates. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery, 2012, Volume: 40, Issue:3 Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Arthralgia; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Breast Neoplasms; Dental Care; Dentist-Patient Relations; Dentists; Diphosphonates; Drug Labeling; Female; Gastrointestinal Diseases; Health Knowledge, Attitudes, Practice; Health Literacy; Humans; Imidazoles; Injections, Intravenous; Interprofessional Relations; Male; Middle Aged; Osteoporosis; Patient Education as Topic; Physician-Patient Relations; Physicians; Prostatic Neoplasms; Risk Factors; Zoledronic Acid	2012
[A case of prostate cancer with disseminated carcinomatosis of bone marrow which responded to Zoledronic acid]. Hinyokika kiyo. Acta urologica Japonica, 2011, Volume: 57, Issue:6 Topics: Aged; Bone Density Conservation Agents; Bone Marrow Neoplasms; Carcinoma; Diphosphonates; Humans; Imidazoles; Male; Neoplasm Seeding; Prostatectomy; Prostatic Neoplasms; Zoledronic Acid	2011
Complete clinical and biological response to zoledronic acid in castrate-resistant prostate cancer metastatic to bone. Anti-cancer drugs, 2012, Volume: 23, Issue:1 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Prostatectomy; Prostatic Neoplasms; Zoledronic Acid	2012
Association of laser phototherapy with PRP improves healing of bisphosphonate-related osteonecrosis of the jaws in cancer patients: a preliminary study. Oral oncology, 2012, Volume: 48, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lasers, Semiconductor; Low-Level Light Therapy; Lung Neoplasms; Male; Middle Aged; Multiple Myeloma; Platelet-Rich Plasma; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Treatment Outcome; Zoledronic Acid	2012
New treatment options for patients with metastatic castration-resistant prostate cancer. Cancer treatment reviews, 2012, Volume: 38, Issue:5 Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Denosumab; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts; Zoledronic Acid	2012
Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade. International journal of urology : official journal of the Japanese Urological Association, 2012, Volume: 19, Issue:2 Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Androgen Antagonists; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Collagen Type I; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Male; Middle Aged; Peptides; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid	2012
Prolonged hypocalcemia after zoledronic acid in a patient with metastatic prostate carcinoma: did zoledronic acid trigger osteoblastic activity and avid calcium uptake? Clinical genitourinary cancer, 2012, Volume: 10, Issue:1 Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Calcium; Diphosphonates; Humans; Hypocalcemia; Imidazoles; Male; Osteoblasts; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid	2012
Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. Journal of medical economics, 2012, Volume: 15, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Male; Markov Chains; Prostatic Neoplasms; Quality-Adjusted Life Years; United States; Zoledronic Acid	2012
Atypical femoral shaft fracture in a patient with non-metastatic prostate cancer on zoledronic acid therapy: effect of therapy or coincidence? Singapore medical journal, 2012, Volume: 53, Issue:3 Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Diphosphonates; Femoral Fractures; Follow-Up Studies; Fracture Fixation, Intramedullary; Fracture Healing; Fractures, Spontaneous; Humans; Imidazoles; Male; Neoplasm Staging; Orchiectomy; Osteoporosis; Prostatectomy; Prostatic Neoplasms; Radiography; Risk Assessment; Zoledronic Acid	2012
Zoledronic acid influences growth, migration and invasive activity of prostate cancer cells in vitro. Prostate cancer and prostatic diseases, 2012, Volume: 15, Issue:3 Topics: Antineoplastic Agents; Apoptosis; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Diphosphonates; Dose-Response Relationship, Drug; Humans; Imidazoles; Male; Prostatic Neoplasms; Signal Transduction; Zoledronic Acid	2012
Leukopenia as a risk factor for osteonecrosis of the jaw in metastatic prostate cancer treated using zoledronic acid and docetaxel. BJU international, 2012, Volume: 110, Issue:11 Pt B Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Docetaxel; Drug Therapy, Combination; Humans; Imidazoles; Incidence; Japan; Jaw Neoplasms; Leukopenia; Male; Middle Aged; Osteonecrosis; Prognosis; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Taxoids; Zoledronic Acid	2012
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis. Journal of medical economics, 2013, Volume: 16, Issue:1 Topics: Antibodies, Monoclonal, Humanized; Bone Neoplasms; Cost-Benefit Analysis; Denosumab; Diphosphonates; Disease Progression; Health Expenditures; Humans; Imidazoles; Male; Markov Chains; Models, Econometric; Prostatic Neoplasms; Quality of Life; Quality-Adjusted Life Years; Survival Analysis; United States; Zoledronic Acid	2013
Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A. BJU international, 2012, Volume: 110, Issue:11 Pt C Topics: Apoptosis; Blotting, Western; Bone Density Conservation Agents; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Humans; Imidazoles; Male; Phosphoprotein Phosphatases; Prostatic Neoplasms; Protein Phosphatase 1; Protein Phosphatase 2; Zoledronic Acid	2012
Zoledronic acid but not somatostatin analogs exerts anti-tumor effects in a model of murine prostatic neuroendocrine carcinoma of the development of castration-resistant prostate cancer. The Prostate, 2013, Volume: 73, Issue:5 Topics: Androgens; Animals; Antineoplastic Agents, Hormonal; Apoptosis; Bone Density Conservation Agents; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cell Movement; Cell Proliferation; Diphosphonates; Disease Models, Animal; Drug Therapy, Combination; Gene Expression Regulation, Neoplastic; Imidazoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Octreotide; Orchiectomy; Prostatic Neoplasms; ras Proteins; Receptors, Somatostatin; Somatostatin; Zoledronic Acid	2013
Skeletal-related events in prostate cancer. Clinical advances in hematology & oncology : H&O, 2012, Volume: 10, Issue:8 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Clinical Trials as Topic; Denosumab; Diphosphonates; Gene Expression; Humans; Imidazoles; Male; Prostate; Prostatic Neoplasms; RANK Ligand; Spinal Cord; Zoledronic Acid	2012
Harms versus benefits with duration of androgen suppression. The Lancet. Oncology, 2012, Volume: 13, Issue:12 Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Brachytherapy; Diphosphonates; Humans; Imidazoles; Leuprolide; Male; Prostatic Neoplasms; Quality of Life; Zoledronic Acid	2012
Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses. Clinical oncology (Royal College of Radiologists (Great Britain)), 2013, Volume: 25, Issue:4 Topics: Aged; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Osteolysis; Peptides; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid	2013
Home-based zoledronic acid infusion therapy in patients with solid tumours: compliance and patient-nurse satisfaction. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013, Volume: 21, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Attitude of Health Personnel; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Feasibility Studies; Female; Fractures, Bone; Home Infusion Therapy; Humans; Imidazoles; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Nurses, Community Health; Osteonecrosis; Patient Compliance; Patient Satisfaction; Physicians; Prospective Studies; Prostatic Neoplasms; Zoledronic Acid	2013
NICE guidance on denosumab for prevention of skeletal-related events in adults with bone metastases from solid tumours. The Lancet. Oncology, 2012, Volume: 13, Issue:12 Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid	2012
Prostate cancer and osteoporosis. Current osteoporosis reports, 2013, Volume: 11, Issue:1 Topics: Adenocarcinoma; Androgen Antagonists; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Male; Osteoporosis; Prostatic Neoplasms; Risk Factors; Zoledronic Acid	2013
Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model. Cancer research, 2002, Oct-01, Volume: 62, Issue:19 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Hindlimb; Humans; Imidazoles; Male; Mice; Mice, SCID; Osteoblasts; Osteoclasts; Prostatic Neoplasms; Radiography; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zoledronic Acid	2002
Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:1 Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cathepsin K; Cathepsins; Cell Division; Diphosphonates; Humans; Imidazoles; Immunohistochemistry; In Situ Nick-End Labeling; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Neoplasm Transplantation; Osteoblasts; Prostatic Neoplasms; Time Factors; Tumor Cells, Cultured; Zoledronic Acid	2003
Zoledronic acid (Zometa): bisphosphonate for prostate cancer/bone metastases. Urologic nursing, 2002, Volume: 22, Issue:6 Topics: Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Male; Prostatic Neoplasms; Zoledronic Acid	2002
Zoledronic acid: a new advance in managing skeletal events in prostate cancer. BJU international, 2003, Volume: 91, Issue:6 Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid	2003
Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. The Journal of urology, 2003, Volume: 170, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Caspase 3; Caspases; Cell Membrane; Cell Survival; Diphosphonates; DNA Fragmentation; Humans; Imidazoles; Male; Mevalonic Acid; Pamidronate; Prostatic Neoplasms; Protein Prenylation; ras Proteins; Zoledronic Acid	2003
The use of bisphosphonates in prostate cancer. BJU international, 2003, Volume: 92, Issue:1 Topics: Antineoplastic Agents; Bone Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid	2003
Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Journal of the National Cancer Institute, 2003, Aug-06, Volume: 95, Issue:15 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Zoledronic Acid	2003
Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Aug-01, Volume: 9, Issue:8 Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Neoplasm Metastasis; Osteoblasts; Prostatic Neoplasms; Time Factors; Zoledronic Acid	2003
Bisphosphonates in prostate cancer: where are we and where should we go? Journal of the National Cancer Institute, 2003, Sep-03, Volume: 95, Issue:17 Topics: Administration, Oral; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Infusions, Intravenous; Male; Neoplasms, Hormone-Dependent; Osteoporosis; Pamidronate; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Zoledronic Acid	2003
Clinical trials test bisphosphonates in hormone-sensitive prostate cancer. Journal of the National Cancer Institute, 2003, Sep-03, Volume: 95, Issue:17 Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Neoplasms; Clodronic Acid; Diphosphonates; Disease-Free Survival; Humans; Imidazoles; Male; Multicenter Studies as Topic; Neoplasm Staging; Neoplasms, Hormone-Dependent; Osteoporosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Zoledronic Acid	2003
Re: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. The Journal of urology, 2003, Volume: 170, Issue:6 Pt 1 Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Resorption; Diphosphonates; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid	2003
[Prostatic carcinoma. Zoledronic acid raises bone density]. Aktuelle Urologie, 2003, Volume: 34, Issue:7 Topics: Bone Density; Densitometry; Diphosphonates; Double-Blind Method; Humans; Imidazoles; Male; Multicenter Studies as Topic; Osteoporosis; Placebos; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Time Factors; Zoledronic Acid	2003
Bone microenvironment-related growth factors modulate differentially the anticancer actions of zoledronic acid and doxorubicin on PC-3 prostate cancer cells. The Prostate, 2004, May-01, Volume: 59, Issue:2 Topics: Antibiotics, Antineoplastic; Bone and Bones; Cell Division; Diphosphonates; Doxorubicin; Drug Administration Schedule; Growth Substances; Humans; Imidazoles; Male; Polyisoprenyl Phosphates; Prostatic Neoplasms; Tumor Cells, Cultured; Zoledronic Acid	2004
Highlights from the 98th annual meeting of the American Urological Association Chicago, IL. Clinical prostate cancer, 2003, Volume: 2, Issue:1 Topics: Androgen Antagonists; Cancer Vaccines; Clinical Trials, Phase II as Topic; Congresses as Topic; Controlled Clinical Trials as Topic; Diphosphonates; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Imidazoles; Male; Osteoporosis; Prognosis; Prostatic Neoplasms; Societies, Medical; Survival Analysis; Tomography, Emission-Computed; Treatment Outcome; United States; Urology; Zoledronic Acid	2003
Prolonged hypocalcemia after treatment with zoledronic acid in a patient with prostate cancer and vitamin D deficiency. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Apr-15, Volume: 22, Issue:8 Topics: Bone Neoplasms; Diphosphonates; Humans; Hypocalcemia; Imidazoles; Male; Prostatic Neoplasms; Vitamin D Deficiency; Zoledronic Acid	2004
High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma. Cancer, 2004, May-01, Volume: 100, Issue:9 Topics: Aged; Aged, 80 and over; Calcitriol; Carcinoma; Cohort Studies; Dexamethasone; Diphosphonates; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Prostatic Neoplasms; Pulse Therapy, Drug; Risk Assessment; Survival Analysis; Treatment Outcome; Zoledronic Acid	2004
Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU international, 2004, Volume: 94, Issue:1 Topics: Apoptosis; Cell Adhesion; Cell Line, Tumor; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Humans; Imidazoles; Male; Prostatic Neoplasms; Protein Prenylation; Zoledronic Acid	2004
Re: A Randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Journal of the National Cancer Institute, 2004, Aug-04, Volume: 96, Issue:15 Topics: Analysis of Variance; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Zoledronic Acid	2004
Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer. European urology, 2004, Volume: 46, Issue:3 Topics: Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Epithelial Cells; Humans; Imidazoles; Male; Matrix Metalloproteinases; Neoplasm Invasiveness; Neoplasm Metastasis; Prostatic Neoplasms; Zoledronic Acid	2004
High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma. Cancer, 2004, Sep-01, Volume: 101, Issue:5 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Dexamethasone; Diphosphonates; Disease Progression; Humans; Imidazoles; Male; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid	2004
Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. International journal of cancer, 2005, Jan-20, Volume: 113, Issue:3 Topics: Antibiotics, Antineoplastic; Apoptosis; Breast Neoplasms; Diphosphonates; Diterpenes; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Female; Humans; Imidazoles; Male; Mevalonic Acid; Prostatic Neoplasms; Time Factors; Tumor Cells, Cultured; Zoledronic Acid	2005
Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. Journal of the National Cancer Institute, 2004, Oct-06, Volume: 96, Issue:19 Topics: Bone Neoplasms; Bone Resorption; Controlled Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid	2004
Re: Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. The Journal of urology, 2004, Volume: 172, Issue:5 Pt 1 Topics: Bone Neoplasms; Cost-Benefit Analysis; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid	2004
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. Journal of the National Cancer Institute, 2005, Jan-05, Volume: 97, Issue:1 Topics: Adult; Aged; Alkaline Phosphatase; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Bone Regeneration; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cohort Studies; Collagen; Collagen Type I; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasms; Peptides; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Risk Assessment; Risk Factors; Time Factors; Zoledronic Acid	2005
Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. Journal of the National Cancer Institute, 2005, Jan-05, Volume: 97, Issue:1 Topics: Analgesics; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Jaw; Male; Necrosis; Osteomyelitis; Osteopetrosis; Pain; Pain Measurement; Pamidronate; Prostatic Neoplasms; Quality of Life; Research Design; Surveys and Questionnaires; Time Factors; Treatment Outcome; Zoledronic Acid	2005
Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment. Urology, 2005, Volume: 65, Issue:1 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alopecia; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; Imidazoles; Life Tables; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Orchiectomy; Pain; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, High-Energy; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome; Zoledronic Acid	2005
Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer. Urology, 2005, Volume: 65, Issue:1 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Diphosphonates; Humans; Imatinib Mesylate; Imidazoles; Male; Neoplasm Proteins; Palliative Care; Piperazines; Prostatic Neoplasms; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Treatment Failure; Zoledronic Acid	2005
Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines. International journal of radiation oncology, biology, physics, 2005, Feb-01, Volume: 61, Issue:2 Topics: Animals; Cell Line, Tumor; Combined Modality Therapy; Diphosphonates; Drug Screening Assays, Antitumor; Humans; Imidazoles; Male; Multiple Myeloma; Prostatic Neoplasms; Radiation Tolerance; Radiotherapy Dosage; Zoledronic Acid	2005
Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. Journal of the National Cancer Institute, 2005, Feb-02, Volume: 97, Issue:3 Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Time Factors; Treatment Outcome; Zoledronic Acid	2005
Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases. Tennessee medicine : journal of the Tennessee Medical Association, 2005, Volume: 98, Issue:2 Topics: Adenocarcinoma; Aged; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Hypocalcemia; Imidazoles; Male; Pain; Prostatic Neoplasms; Zoledronic Acid	2005
Zoledronic acid mediates Ras-independent growth inhibition of prostate cancer cells. Oncology research, 2005, Volume: 15, Issue:1 Topics: Blotting, Western; Cell Proliferation; Diphosphonates; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Imidazoles; Male; Prostatic Neoplasms; Protein Prenylation; Tumor Cells, Cultured; Zoledronic Acid	2005
Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer. Cancer research, 2005, May-01, Volume: 65, Issue:9 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Bone and Bones; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imatinib Mesylate; Imidazoles; Immunohistochemistry; Male; Mice; Mice, Nude; Osteoclasts; Paclitaxel; Piperazines; Prostatic Neoplasms; Pyrimidines; Zoledronic Acid	2005
Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. Prostate cancer and prostatic diseases, 2005, Volume: 8, Issue:3 Topics: Animals; Antibodies; Antineoplastic Agents; Apoptosis; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Cell Proliferation; Densitometry; Diphosphonates; Glycoproteins; Humans; Imidazoles; Immunoglobulin Fc Fragments; In Vitro Techniques; Male; Mice; Mice, SCID; Neoplasm Metastasis; Osteoclasts; Osteolysis; Osteoprotegerin; Prostatic Neoplasms; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Tibia; Time Factors; Zoledronic Acid	2005
Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta oncologica (Stockholm, Sweden), 2005, Volume: 44, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imidazoles; Male; Mitosis; Prostatic Neoplasms; Taxoids; Zoledronic Acid	2005
Zoledronic acid sensitizes tumor cells to radiation: in response to Algur et al. (Int J Radiat Oncol Biol Phys 2005;61:535-542). International journal of radiation oncology, biology, physics, 2005, Nov-01, Volume: 63, Issue:3 Topics: Animals; Cell Cycle; Cell Line, Tumor; Combined Modality Therapy; Diphosphonates; Humans; Imidazoles; Male; Multiple Myeloma; Prostatic Neoplasms; Proto-Oncogene Proteins p21(ras); Radiation Tolerance; Radiation-Sensitizing Agents; Zoledronic Acid	2005
Prostate cancer presenting with normal serum PSA levels and boney metastases treated with zoledronic acid. Journal of pain & palliative care pharmacotherapy, 2005, Volume: 19, Issue:3 Topics: Adenocarcinoma; Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid	2005
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2005, Volume: 63, Issue:11 Topics: Abscess; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Dental Caries; Dexamethasone; Diphosphonates; Drug Interactions; Female; Humans; Hyperostosis; Imidazoles; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Osteopetrosis; Osteoporosis; Pamidronate; Periodontitis; Prostatic Neoplasms; Risk Factors; Tooth Extraction; Zoledronic Acid	2005
[Osteoporosis and anti-androgenic therapy in case of prostate cancer]. Revue medicale suisse, 2005, Oct-05, Volume: 1, Issue:35 Topics: Androgen Antagonists; Bone Resorption; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Osteoporosis; Prognosis; Prostatic Neoplasms; Risk Factors; Survival; Zoledronic Acid	2005
Bone microenvironment-related growth factors, zoledronic acid and dexamethasone differentially modulate PTHrP expression in PC-3 prostate cancer cells. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2005, Volume: 37, Issue:10 Topics: Bone and Bones; Cell Line, Tumor; Dexamethasone; Diphosphonates; Fibroblast Growth Factor 2; Fluorescent Antibody Technique; Growth Substances; Humans; Imidazoles; Insulin-Like Growth Factor I; Interleukin-6; Male; Parathyroid Hormone-Related Protein; Prostatic Neoplasms; Receptor, Parathyroid Hormone, Type 1; Transforming Growth Factor beta; Zoledronic Acid	2005
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Follow-Up Studies; Greece; Humans; Imidazoles; Incidence; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Prospective Studies; Prostatic Neoplasms; Risk Factors; Time Factors; Treatment Failure; Zoledronic Acid	2005
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. Endocrine-related cancer, 2005, Volume: 12, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Diphosphonates; Female; Gefitinib; Humans; Imidazoles; Male; Mice; Mice, Nude; Prostatic Neoplasms; Proteins; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays; Zoledronic Acid	2005
Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC cancer, 2006, Jan-17, Volume: 6 Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Docetaxel; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Imidazoles; Male; Mice; Mice, SCID; Prostatic Neoplasms; Random Allocation; Taxoids; Tibia; Transplantation, Heterologous; Zoledronic Acid	2006
Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases. Bone, 2006, Volume: 39, Issue:1 Topics: Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Pain; Palliative Care; Prostatic Neoplasms; Strontium Radioisotopes; Time Factors; Treatment Outcome; Zoledronic Acid	2006
Evaluation of human fetal bone implants in SCID mice as a model of prostate cancer bone metastasis. Oncology reports, 2006, Volume: 15, Issue:3 Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Transplantation; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Dose-Response Relationship, Drug; Fetus; Green Fluorescent Proteins; Humans; Imidazoles; Luciferases; Luminescent Measurements; Male; Mice; Mice, SCID; Plasmids; Prostatic Neoplasms; Transfection; Xenograft Model Antitumor Assays; Zoledronic Acid	2006
Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. BMC cancer, 2006, Mar-15, Volume: 6 Topics: Alkyl and Aryl Transferases; Bone Density Conservation Agents; Cell Proliferation; Cholesterol; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Protein Prenylation; Tumor Cells, Cultured; Zoledronic Acid	2006
Jaw complications in breast and prostate cancer patients treated with zoledronic acid. Acta oncologica (Stockholm, Sweden), 2006, Volume: 45, Issue:2 Topics: Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Osteonecrosis; Prostatic Neoplasms; Zoledronic Acid	2006
Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents. Oncology, 2006, Volume: 70, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cytoplasm; Deoxycytidine; Diphosphonates; DNA Fragmentation; Drug Antagonism; Drug Synergism; Epirubicin; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemcitabine; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Prostatic Neoplasms; Zoledronic Acid	2006
Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU international, 2006, Volume: 97, Issue:6 Topics: Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Imidazoles; Magnesium Deficiency; Male; Prostatic Neoplasms; Urogenital Neoplasms; Zoledronic Acid	2006
Additive/synergistic anti-tumoral effects of the combination of docetaxel and zoledronic acid on prostate cancer cells: possible mechanisms? Acta oncologica (Stockholm, Sweden), 2006, Volume: 45, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Diphosphonates; Docetaxel; Drug Synergism; Humans; Imidazoles; Male; Multiple Myeloma; Prostatic Neoplasms; Taxoids; Zoledronic Acid	2006
[The effect of bisphosphonates on bone metastasis of hormone-refractory prostate cancer]. Hinyokika kiyo. Acta urologica Japonica, 2006, Volume: 52, Issue:6 Topics: Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid	2006
R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. Journal of cellular physiology, 2007, Volume: 211, Issue:2 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-Associated Death Protein; Caspases; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Imidazoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Quinolones; ras Proteins; Signal Transduction; Time Factors; Xenograft Model Antitumor Assays; Zoledronic Acid	2007
Effect of zoledronic acid on metastatic hormone-refractory prostate cancer resistant to taxane, estramustine, carboplatin, and dexamethasone. International journal of urology : official journal of the Japanese Urological Association, 2007, Volume: 14, Issue:1 Topics: Aged; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Bone Neoplasms; Bridged-Ring Compounds; Carboplatin; Dexamethasone; Diphosphonates; Drug Resistance, Neoplasm; Estramustine; Humans; Imidazoles; Male; Prostatic Neoplasms; Taxoids; Zoledronic Acid	2007
Docetaxel and beyond. European urology, 2007, Volume: 51, Issue:5 Topics: Antineoplastic Agents; Bone Neoplasms; Carboplatin; Diphosphonates; Docetaxel; Estramustine; Humans; Imidazoles; Male; Prostatic Neoplasms; Taxoids; Zoledronic Acid	2007
Outcomes of patients with prostate cancer receiving zoledronic acid or pamidronate for prevention of skeletal-related events. Pharmacotherapy, 2007, Volume: 27, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Cohort Studies; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Pamidronate; Prostatic Neoplasms; Retrospective Studies; Treatment Outcome; Zoledronic Acid	2007
Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2007, Volume: 15, Issue:7 Topics: Aged; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Musculoskeletal System; Neoplasm Metastasis; Prognosis; Prostatic Neoplasms; Quality of Life; Risk Factors; Survival; Treatment Outcome; Zoledronic Acid	2007
Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity. Cancer immunology, immunotherapy : CII, 2007, Volume: 56, Issue:8 Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Burkitt Lymphoma; Carcinoma; Cell Line, Tumor; Cisplatin; Colorectal Neoplasms; Concanavalin A; Cytotoxicity, Immunologic; Diphosphonates; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Genes, T-Cell Receptor delta; Genes, T-Cell Receptor gamma; Humans; Imidazoles; Interferon-gamma; Lovastatin; Lung Neoplasms; Male; Membrane Glycoproteins; Neoplasms; Perforin; Pore Forming Cytotoxic Proteins; Prostatic Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Urinary Bladder Neoplasms; Vincristine; Zoledronic Acid	2007
The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer, 2007, Mar-15, Volume: 109, Issue:6 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Renal Insufficiency; Retrospective Studies; Risk Factors; Zoledronic Acid	2007
Decreases in pain at rest and movement-related pain during zoledronic acid treatment in patients with bone metastases due to breast or prostate cancer: a pilot study. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2007, Volume: 15, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Italy; Male; Middle Aged; Pain Measurement; Pilot Projects; Prostatic Neoplasms; Zoledronic Acid	2007
Annual zoledronic acid: is less more? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Mar-20, Volume: 25, Issue:9 Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Drug Administration Schedule; Fractures, Bone; Humans; Imidazoles; Male; Osteoporosis; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid	2007
New treatment strategies in the management of hormone refractory prostate cancer (HRPC): only chemotherapy? European urology, 2007, Volume: 52, Issue:4 Topics: Antineoplastic Agents; Diphosphonates; Docetaxel; Drug Resistance, Neoplasm; Humans; Imidazoles; Male; Prostatic Neoplasms; Taxoids; Vinblastine; Vinorelbine; Zoledronic Acid	2007
Re: Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer: C. W. Ryan, D. Huo, L. M. Demers, T. M. Beer and L. V. Lacerna. J Urol 2006; 176: 972-978. The Journal of urology, 2007, Volume: 177, Issue:4 Topics: Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Male; Orchiectomy; Prostatic Neoplasms; Risk Factors; Time Factors; Zoledronic Acid	2007
Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis. Acta oncologica (Stockholm, Sweden), 2007, Volume: 46, Issue:5 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Prostatic Neoplasms; Zoledronic Acid	2007
The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer. Acta oncologica (Stockholm, Sweden), 2007, Volume: 46, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphosphonates; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imidazoles; Male; Minichromosome Maintenance Complex Component 2; Neoplasms, Hormone-Dependent; Nuclear Proteins; Prostatic Neoplasms; Taxoids; Zoledronic Acid	2007
Patient quality of life safeguarding: the primary aim in nonmetastatic prostate cancer patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Aug-01, Volume: 25, Issue:22 Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Boston; Diphosphonates; Drug Administration Schedule; Fractures, Bone; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Osteoporosis; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Zoledronic Acid	2007
Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer research, 2007, Aug-01, Volume: 67, Issue:15 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Drug Therapy, Combination; Feasibility Studies; Humans; Imidazoles; Immunotherapy; Interleukin-2; Lymphocyte Activation; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; Remission Induction; Salvage Therapy; T-Lymphocytes; Treatment Outcome; Zoledronic Acid	2007
Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2008, Volume: 62, Issue:2 Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Case-Control Studies; Cathepsin K; Cathepsins; Cystatin C; Cystatins; Diphosphonates; Disease Progression; Drug Monitoring; Enzyme-Linked Immunosorbent Assay; Female; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Prostatic Hyperplasia; Prostatic Neoplasms; ROC Curve; Zoledronic Acid	2008
Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid. Medicina oral, patologia oral y cirugia bucal, 2007, Sep-01, Volume: 12, Issue:5 Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Prostatic Neoplasms; Zoledronic Acid	2007
The role of surgery in jaw bone necrosis associated with long-term use of bisphosphonates. Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:3 Topics: Adenocarcinoma; Bone Neoplasms; Bone Plates; Bone Screws; Breast Neoplasms; Cutaneous Fistula; Diphosphonates; Female; Humans; Imidazoles; Male; Mandible; Mandibular Diseases; Middle Aged; Necrosis; Oral Fistula; Osteolysis; Osteomyelitis; Pamidronate; Prostatic Neoplasms; Recurrence; Tomography, X-Ray Computed; Zoledronic Acid	2008
[Mediastinal lymph nodes during the course of a metastatic prostate cancer]. Actas urologicas espanolas, 2007, Volume: 31, Issue:6 Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyproterone; Diphosphonates; Estramustine; Fatal Outcome; Flutamide; Humans; Imidazoles; Ketoconazole; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinum; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Radionuclide Imaging; Skin Neoplasms; Triptorelin Pamoate; Zoledronic Acid	2007
Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases. Clinical genitourinary cancer, 2007, Volume: 5, Issue:6 Topics: Adenocarcinoma; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Hypocalcemia; Imidazoles; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Zoledronic Acid	2007
Relevance of a new rat model of osteoblastic metastases from prostate carcinoma for preclinical studies using zoledronic acid. International journal of cancer, 2008, Feb-15, Volume: 122, Issue:4 Topics: Animals; Apoptosis; Bone Density Conservation Agents; Bone Marrow Cells; Bone Neoplasms; Bone Remodeling; Cell Cycle; Cell Proliferation; Diphosphonates; Disease Models, Animal; Humans; Imidazoles; Male; Mice; Mice, Inbred C3H; Osteoblasts; Osteogenesis; Osteosarcoma; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Tumor Cells, Cultured; Zoledronic Acid	2008
Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro. Molecular cancer therapeutics, 2007, Volume: 6, Issue:11 Topics: Antineoplastic Agents; Benzamides; Cell Death; Cell Line, Tumor; Diphosphonates; Drug Screening Assays, Antitumor; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Imidazoles; Lovastatin; Male; Methionine; Mitochondria; Prostatic Neoplasms; Vorinostat; Zoledronic Acid	2007
Death of a clinical trial: a speculative inclusion criterion gone wrong. Internal medicine journal, 2007, Volume: 37, Issue:12 Topics: Antineoplastic Agents; Australia; Chemotherapy, Adjuvant; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Zoledronic Acid	2007
Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases. European journal of nuclear medicine and molecular imaging, 2008, Volume: 35, Issue:4 Topics: Bone Density Conservation Agents; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Humans; Imidazoles; Injections, Intravenous; Male; Metabolic Clearance Rate; Neoplasm Metastasis; Organometallic Compounds; Organophosphorus Compounds; Prostatic Neoplasms; Radioisotopes; Samarium; Zoledronic Acid	2008
[Androgen-independent prostate cancer with bone metastasis successfully treated by intravenous administration of zoledronic acid and diethylstilbestrol diphosphate]. Hinyokika kiyo. Acta urologica Japonica, 2007, Volume: 53, Issue:12 Topics: Aged; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Bone Neoplasms; Diethylstilbestrol; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Injections, Intravenous; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid	2007
Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages. Cancer immunology, immunotherapy : CII, 2008, Volume: 57, Issue:10 Topics: Antineoplastic Agents; Cell Communication; Cell Line, Tumor; Cell Movement; Diphosphonates; Flow Cytometry; Humans; Imidazoles; Macrophage Activation; Macrophages; Male; Matrix Metalloproteinase 9; Polymerase Chain Reaction; Prostatic Neoplasms; T-Lymphocytes; Zoledronic Acid	2008
RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. The Prostate, 2008, Jun-01, Volume: 68, Issue:8 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Docetaxel; Everolimus; Humans; Imidazoles; Male; Mice; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Sirolimus; Taxoids; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Zoledronic Acid	2008
Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C. Medical oncology (Northwood, London, England), 2009, Volume: 26, Issue:1 Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cystatin C; Diphosphonates; Female; Humans; Imidazoles; Interleukin-6; Male; Middle Aged; Osteoporosis; Prostate-Specific Antigen; Prostatic Neoplasms; ROC Curve; Zoledronic Acid	2009
Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions. The Prostate, 2008, Jul-01, Volume: 68, Issue:10 Topics: Adenocarcinoma; Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Transformed; Diphosphonates; Disease Models, Animal; Dogs; Imidazoles; Incidence; Luminescent Proteins; Male; Mice; Mice, Nude; Osteoclasts; Osteolysis; Prostatic Neoplasms; Radiography; Zoledronic Acid	2008
Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer research, 2000, Jun-01, Volume: 60, Issue:11 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Adhesion; Cell Cycle; Cell Movement; Clodronic Acid; Collagen; Diphosphonates; Dose-Response Relationship, Drug; Drug Combinations; Flow Cytometry; Fluorometry; Humans; Ibandronic Acid; Imidazoles; Laminin; Male; Matrix Metalloproteinases; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Prostatic Neoplasms; Proteoglycans; Pyridines; Pyridinium Compounds; Tumor Cells, Cultured; Zinc; Zoledronic Acid	2000
Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM). Breast cancer (Tokyo, Japan), 2000, Volume: 7, Issue:4 Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcemia; Imidazoles; Male; Osteoclasts; Osteoporosis; Pamidronate; Prostatic Neoplasms; Zoledronic Acid	2000
Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer research, 2001, Mar-15, Volume: 61, Issue:6 Topics: Antineoplastic Agents; Cell Cycle; Cell Division; Cell Survival; Diphosphonates; Growth Inhibitors; Humans; Imidazoles; Male; Pamidronate; Prostatic Neoplasms; Tumor Cells, Cultured; Zoledronic Acid	2001